DSS, INC. 10-K

ITEM 8 - FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA Financial Statements DSS, INC. AND SUBSIDIARIES TABLE OF CONTENTS Page Reports of Independent Registered Public Accounting Firm (PCAOB ID: 7000 ) 29 Reports of Independent Registered Public Accounting Firm (PCAOB ID: 606 ) 31 Consolidated Financial Statements: Consolidated Balance Sheets 32 Consolidated Statements of Operations 33 Consolidated Statements of Changes in Stockholders’ Equity 34 Consolidated Statements of Cash Flows 35 Notes to the Consolidated Financial Statements 36 28 REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM To the Board of Directors of and Stockholders of DSS, INC. Opinion on the Consolidated Financial Statements We have audited the accompanying consolidated balance sheet of DSS, INC. and its subsidiaries (collectively, the “Company”) as of December 31, 2025, and the related consolidated statement of operations, consolidated statement of changes in stockholders’ equity, and consolidated statement of cash flows for the year ended December 31, 2025, including the related notes (collectively referred to as the “consolidated financial statements”). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2025 and the results of its operations and its cash flows for the year ended December 31, 2025, in conformity with accounting principles generally accepted in the United States of America . Going Concern The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 2 to the financial statements, the Company has incurred net losses, losses from operations and negative cashflow from operations. These factors raise substantial doubt about the Company’s ability to continue as a going concern. Management’s plans in regard to this matter are also discussed in Note 2. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. Basis for Opinion These consolidated financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s consolidated financial statements based on our audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audit, we are required to obtain an understanding of internal control over financial reporting, but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion. Our audit included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audit also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audit provides a reasonable basis for our opinion. Emphasis of Matter The Company has significant transactions with related parties which are described in Notes 20 of the consolidated financial statements. Transactions involving related parties cannot be presumed to be carried out on an arm’s length basis, as the requisite condition of competitive, free market dealings may not exist. Critical Audit Matters Critical audit matters are matters arising from the current year audit of the consolidated financial statements that were communicated or required to be communicated to the audit committee and that (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate. 29 Investments in Real Estate As disclosed in Note 2 and 9 to the consolidated financial statements, the Company owns real estate properties through their subsidiaries with a net book value of approximately $16,612,000. We identified the valuation of the real estate to be a critical audit matter. The principal consideration for our determination of management’s assessment of impairment of the real estate as a critical audit matter is the high degree of subjective auditor judgment associated with evaluating management’s determination of impairment of the real estate properties, which is primarily due to the complexity of the valuation models used and the sensitivity of the underlying significant assumptions. The key assumptions used within the valuation models included site valuations and various approaches such as cost, sales comparison, etc. The calculated fair values are sensitive to changes in these key assumptions. How the Critical Audit Matter was addressed in the Audit Our audit procedures related to the determination of the fair value of the real estate properties included the following, among others: a) We obtained management’s rollforward of investments in real estate from December 31, 2024, to December 31, 2025 and tested any material additions or disposals by vouching to the supporting documents . b) We obtained third party valuations from management that assess the fair value of the properties. c) We assessed the qualifications, competency and objectivity of third-party specialist. d) We engaged a valuation firm to review the valuation reports provided by management to determine if the reports were reasonable and acceptable based on the methodologies used by management’s third-party valuation firm. We also assessed the qualifications and competence of the valuation firm. e) We compared the net book value of the real estate properties to the fair values of the properties per the third-party valuations to determine if the carrying value is less than fair value and impairment was addressed properly. f) We assessed the sufficiency of the Company’s disclosure of its accounting for these real estate properties included in Notes 2 and 9. Evaluation of Intangible Assets and Goodwill for Impairment As disclosed in Notes 2 and 10 to the consolidated financial statements, the Company holds Intangible Assets and Goodwill through its subsidiaries with a net book value of approximately $17,034,000 and $1,769,000, respectively. We identified the value of Intangible Assets and Goodwill to be a critical audit matter. The principal consideration for our determination of management’s assessment of impairment of the Intangible Assets and Goodwill as a critical audit matter is the high degree of subjective auditor judgment associated with evaluating management’s analysis, which is primarily due to the subjectivity of management’s qualitative assumptions. The conclusion of the impairment analysis is sensitive to changes in these key assumptions. How the Critical Audit Matter was addressed in the Audit Our audit procedures related to the evaluation of the Intangible Assets and Goodwill for impairment included the following, among others: a) We obtained management’s rollforward of Intangible Assets from December 31, 2024, to December 31, 2025 and tested any material additions and disposals by vouching to the supporting documents. b) We obtained management’s qualitative analysis that assessed the Intangible Assets and Goodwill. c) We evaluated the reasonableness of management’s analysis of relevant events and circumstances, such as macroeconomic conditions, industry considerations, and entity-specific financial performance. We independently validated key points in management’s assessment by comparing their qualitative conclusions against internal financial trends and external market data d) We assessed the sufficiency of the Company’s disclosure of its accounting for Intangible Assets and Goodwill included in Notes 3 and 11. We have served as the Company’s auditor since 2025 HTL International, LLC Houston, Texas March 31, 2026 30 REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM To the Board of Directors and Stockholders of DSS, Inc. Opinion on the Consolidated Financial Statements We have audited the accompanying consolidated balance sheet of DSS, Inc. (the “Company”) as of December 31, 2024, and the related consolidated statement of operations, stockholders’ equity, and cash flows for the year ended December 31, 2024, and the related notes (collectively referred to as the “financial statements”). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2024, and the results of its operations and its cash flows for the year ended December 31, 2024, in conformity with accounting principles generally accepted in the United States of America. Basis for Opinion These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s financial statements based on our audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audit, we are required to obtain an understanding of internal control over financial reporting, but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion. Our audit included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audit also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audit provides a reasonable basis for our opinion. Critical Audit Matters The critical audit matters communicated below are matters arising from the current period audit of the financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate. Investments in Real Estate As described in Note 2 to the consolidated financial statements, the Company owns real estate properties through their subsidiaries with a net book value of approximately $45,158,000, which are classified as held for sale. We identified the valuation of the real estate to be a critical audit matter. The principal consideration for our determination of management’s assessment of impairment of the real estate as a critical audit matter is the high degree of subjective auditor judgment associated with evaluating management’s determination of impairment of the real estate properties, which is primarily due to the complexity of the valuation models used and the sensitivity of the underlying significant assumptions. The key assumptions used within the valuation models included site valuations and various approaches such as cost, sales comparison, etc. The calculated fair values are sensitive to changes in these key assumptions. How the Critical Audit Matter was addressed in the Audit Our audit procedures related to the determination of the fair value of the real estate properties included the following, among others: a) We obtained management’s roll forward of investments in real estate from December 31, 2023, to December 31, 2024 and tested any material additions by vouching to invoices and contracts. b) We obtained third party valuations that assess the fair value of the properties from management. c) We assessed the qualifications and competence of management and the qualifications, competence and objectivity of third-party specialist. d) We engaged a valuation firm to review the valuation reports provided by management to determine if the reports were reasonable and acceptable based on the methodologies used by management’s third-party valuation firm. We also assessed the qualifications and competence of the valuation firm. e) We compared the net book value of the real estate properties to the fair values of the properties per the third-party valuations to determine if the carrying value is less than fair value and impairment was addressed properly. During the year ended December 31, 2024, Management reclassified the land and building related to AMRE Shelton to assets held for sale. f) We assessed the sufficiency of the Company’s disclosure of its accounting for these real estate properties included in Notes 2 and 7. Evaluation of Intangible Assets and Goodwill for Impairment As described in Notes 2 and 10 to the consolidated financial statements, the Company holds Intangible Assets and Goodwill through its subsidiaries with a net book value of approximately $18,890,000 and $1,769,000, respectively. We identified the value of Intangible Assets and Goodwill to be a critical audit matter. The principal consideration for our determination of management’s assessment of impairment of the Intangible Assets and Goodwill as a critical audit matter is the high degree of subjective auditor judgment associated with evaluating management’s determination of impairment of Intangible Assets and Goodwill, which is primarily due to the complexity of the valuation models used and the sensitivity of the underlying significant assumptions. The key assumptions used within the valuation models included qualitative and quantitative assessments. The calculated fair values are sensitive to changes in these key assumptions. How the Critical Audit Matter was addressed in the Audit Our audit procedures related to the determination of the fair value of the Intangible Assets and Goodwill included the following, among others: a) We obtained management’s rollforward of Intangible Assets and Goodwill from December 31, 2023, to December 31, 2024 and tested any material additions and disposals by vouching to agreements. b) We obtained management’s qualitative and quantitative assessments and third-party valuations that assess the fair value of the Intangible Assets and Goodwill. c) We assessed the qualifications and competence of management and the qualifications, competence and objectivity of third-party specialists. d) We reviewed the valuation reports provided by management to determine if the reports were reasonable and acceptable based on the methodologies used by management’s third-party valuation firm. e) We audited the critical inputs used in the valuation calculations and utilized the services of an independent auditor engaged specialist to ensure the methodologies and assumptions utilized by the Company’s independent specialists were reasonable and in accordance with industry standards. f) We assessed the sufficiency of the Company’s disclosure of its accounting for Intangible Assets and Goodwill included in Notes 2 and 10. Grassi & Co., CPAs, P.C. We served as the Company’s auditor from 2022 to 2025. Jericho, New York March 31, 2025 31 DSS, INC. AND SUBSIDIARIES Consolidated Balance Sheets As of December 31, 2025 As of December 31, 2024 ASSETS Current assets: Cash and cash equivalents $ 6,214,000 $ 11,431,000 Restricted cash 100,000 - Accounts receivable, net 2,254,000 3,068,000 Inventory 1,998,000 2,442,000 Investment in trading securities 2,694,000 2,878,000 Assets held for sale - 45,158,000 Current portion of notes receivable, net 198,000 240,000 Current portion of notes receivable - related party 238,000 337,000 Current portion of notes receivable 238,000 337,000 Prepaid expenses and other current assets 649,000 1,141,000 Total current assets 14,345,000 66,695,000 Property, plant and equipment, net 4,819,000 5,381,000 Investments in real estate, net 16,637,000 - Investments, cost method 500,000 500,000 Investments, equity method 113,000 129,000 Investment in equity securities 6,517,000 6,333,000 Notes receivable, net - 17,000 Notes receivable - related party, net - 112,000 Notes receivable - 112,000 Other assets 71,000 162,000 Right-of-use assets 5,825,000 6,465,000 Goodwill 1,769,000 1,769,000 Other intangible assets, net 17,034,000 18,890,000 Total assets $ 67,630,000 $ 106,453,000 LIABILITIES AND STOCKHOLDERS’ EQUITY Current liabilities: Accounts payable $ 2,597,000 $ 2,793,000 Accrued expenses and deferred revenue 1,725,000 2,651,000 Other current liabilities 4,367,000 4,193,000 Accrued interest on long-term debt 7,162,000 5,008,000 Current portion of lease liability 611,000 606,000 Current portion of long-term debt, net 30,343,000 642,000 Current portion of long-term debt on assets held-for-sale, net - 48,526,000 Convertible note payable - related party 503,000 - Current portion of long-term debt - related party, net 188,000 609,000 Current portion of long-term debt 188,000 609,000 Total current liabilities 47,496,000 65,028,000 Long-term debt, net 5,727,000 2,398,000 Long term lease liability 5,692,000 6,311,000 Total liabilities 58,915,000 73,737,000 Commitments and contingencies (Note 16) - - Stockholders’ equity (deficit) Preferred stock, $ .02 par value; 47,000 shares authorized, zero shares issued and outstanding - - Common stock, $ .02 par value; 200,000,000 shares authorized, 9,092,518 shares issued and outstanding ( 8,092,518 on December 31, 2024) 182,000 161,000 Additional paid-in capital 325,987,000 322,852,000 Accumulated deficit ( 327,001,000 ) ( 303,072,000 ) Total stockholders’ equity of the Company ( 832,000 ) 19,941,000 Non-controlling interest in subsidiaries 9,547,000 12,775,000 Total stockholders’ equity 8,715,000 32,716,000 Total liabilities and stockholders’ equity $ 67,630,000 $ 106,453,000 See accompanying notes to the consolidated financial statements. 32 DSS, INC. AND SUBSIDIARIES Consolidated Statements of Operations For the year ended December 31, 2025 For the year ended December 31, 2024 Revenue: Printed products $ 18,085,000 $ 16,107,000 Rental 1,236,000 1,792,000 Commercial lending 45,000 226,000 Commission 1,353,000 972,000 Biotechnology 38,000 - Total revenue 20,757,000 19,097,000 Costs and expenses: Cost of revenue 22,926,000 23,539,000 Selling, general and administrative (including stock-based compensation) 12,265,000 38,154,000 Total costs and expenses 35,191,000 61,693,000 Operating loss ( 14,434,000 ) ( 42,596,000 ) Other income (expense): Interest income 19,000 238,000 Interest income on note receivable, related party 32,000 102,000 Dividend income 20,000 - Other 11,000 218,000 Interest expense ( 266,000 ) ( 283,000 ) Foreign Currency Translation Adjustment - ( 6,000 ) Gain on extinguishment of debt 595,000 - (Loss)/gain on equity method investment ( 16,000 ) 1,000 (Loss) gain on investments ( 807,000 ) 224,000 Impairment of investment - ( 782,000 ) Impairment of intangible assets ( 600,000 ) - Impairment of real estate assets ( 2,420,000 ) ( 7,288,000 ) Provision for loan losses - ( 3,691,000 ) (Loss)/gain on sale real estate assets ( 9,622,000 ) 165,000 Loss from operations before income taxes ( 27,488,000 ) ( 53,698,000 ) Income tax benefit - ( 8,000 ) Net loss $ ( 27,488,000 ) $ ( 53,706,000 ) Loss from operations attributed to noncontrolling interest 3,559,000 6,810,000 Net loss attributable to DSS common stockholders $ ( 23,929,000 ) $ ( 46,896,000 ) Loss per common share attributable to common stockholders Basic $ ( 2.66 ) $ ( 6.63 ) Diluted $ ( 2.66 ) $ ( 6.63 ) Shares used in computing loss per common share: Basic 8,991,425 7,072,377 Diluted 8,991,425 7,702,377 See accompanying notes to the consolidated financial statements. 33 DSS, INC. AND SUBSIDIARIES Consolidated Statements of Changes in Stockholders’ Equity For the Years Ended December 31, - Common Stock Preferred Stock Additional Paid-in Accumulated Total DSS Non- controlling Interest in Shares Amount Shares Amount Capital Deficit Equity Subsidiary Total Balance, December 31, 2023 7,066,772 $ 140,000 - $ - $ 319,963,000 $ ( 256,176,000 ) $ 63,927,000 $ 19,287,000 $ 83,214,000 - Issuance of common stock, net of expenses 1,025,746 20,000 - - 980,000 - 1,000,000 - 1,000,000 Stock based payments - - - 19,000 - 19,000 - 19,000 Issuance of common stock, net of expenses - Impact BioMedical, Inc. - 1,000 - - 1,890,000 - 1,891,000 298,000 2,189,000 Net loss - - - - - ( 46,896,000 ) ( 46,896,000 ) ( 6,810,000 ) ( 53,706,000 ) Balance, December 31, 2024 8,092,518 $ 161,000 - $ - $ 322,852,000 $ ( 303,072,000 ) $ 19,941,000 $ 12,775,000 $ 32,716,000 - Balance, December 31, 2024 8,092,518 161,000 - - 322,852,000 ( 303,072,000 ) 19,941,000 12,775,000 32,716,000 Balance 8,092,518 161,000 - - 322,852,000 ( 303,072,000 ) 19,941,000 12,775,000 32,716,000 Issuance of common stock, net of expenses - Impact BioMedical, Inc. - 1,000 - - 2,082,000 - 2,083,000 331,000 2,414,000 Issuance of common stock for award 1,000,000 20,000 - - 850,000 - 870,000 - 870,000 Stock based payments for professional services rendered for Impact Bio - - - - 190,000 - 190,000 - 190,000 Stock based payments - - - - 13,000 - 13,000 - 13,000 Net loss - - - - - ( 23,929,000 ) ( 23,929,000 ) ( 3,559,000 ) ( 27,488,000 ) Balance, December 31, 2025 9,092,518 $ 182,000 - $ - $ 325,987,000 $ ( 327,001,000 ) $ ( 832,000 ) $ 9,547,000 $ 8,715,000 Balance 9,092,518 $ 182,000 - $ - $ 325,987,000 $ ( 327,001,000 ) $ ( 832,000 ) $ 9,547,000 $ 8,715,000 See accompanying notes to the consolidated financial statements. 34 DSS, INC. AND SUBSIDIARIES Consolidated Statements of Cash Flows For the year ended December 31, 2025 For the year ended December 31, 2024 Cash flows from operating activities: Net loss $ ( 27,488,000 ) $ ( 53,706,000 ) Adjustments to reconcile net loss to net cash used by operating activities: Depreciation and amortization 2,890,000 2,239,000 Issuance of common stock for reward 870,000 - Stock based payments for professional services rendered 190,000 - Stock based payments to employees and directors 13,000 19,000 (Loss) gain on equity method investment 16,000 ( 1,000 ) Unrealized loss (gain) on investment in marketable securities 531,000 ( 224,000 ) Amortization of operating lease ROU assets 640,000 745,000 Write off of inventory 419,000 - Provision for inventory obsolescence ( 127,000 ) - Loss (gain) on sale of real estate assets 9,622,000 ( 14,000 ) Impairment of fixed assets - 264,000 Impairment of investments of investments at cost - 782,000 Impairment of real estate 2,420,000 7,288,000 Impairment of intangibles 600,000 - Provision for loan losses 20,000 4,398,000 Gain on extinguishment of debt ( 595,000 ) - Impairment of goodwill - 25,093,000 Decrease (increase) in assets: Accounts receivable 558,000 1,142,000 Inventory 152,000 377,000 Prepaid expenses and other current assets 642,000 778,000 Investment in trading securities ( 316,000 ) ( 3,327,000 ) Other assets 91,000 ( 65,000 ) Increase (decrease) in liabilities: Accounts payable ( 196,000 ) ( 861,000 ) Accrued expenses ( 926,000 ) 140,000 ROU liabilities ( 614,000 ) ( 686,000 ) Accrued interest on notes payable 2,083,000 3,648,000 Other liabilities ( 624,000 ) 3,210,000 Net cash used by operating activities ( 9,129,000 ) ( 8,761,000 ) Cash flows from investing activities: Purchase of property, plant and equipment ( 268,000 ) ( 133,000 ) Purchase of real estate ( 38,000 ) ( 140,000 ) Proceeds from sale of real estate 15,713,000 - Proceeds from sale of equity investments - 3,023,000 Proceeds from disposal of property, plant and equipment - 5,609,000 Proceeds from sale of investment, related party 2,414,000 - Issuance of new notes receivable, net origination fees - ( 459,000 ) Payments received on notes receivable 250,000 4,132,000 Payments received on notes receivable, related party - 106,000 Net cash provided by investing activities 18,071,000 12,138,000 Cash flows from financing activities: Payments of long-term debt ( 17,809,000 ) ( 2,626,000 ) Borrowings of long-term debt, net 3,250,000 876,000 Borrowings of convertible note payable - related party 500,000 - Issuances of common stock, net of issuance costs - 3,189,000 Net cash provided (used) by financing activities ( 14,059,000 ) 1,439,000 Net increase (decrease) in cash ( 5,117,000 ) 4,816,000 Cash and cash equivalents at beginning of year 11,431,000 6,615,000 Cash and cash equivalents and restricted cash at end of period $ 6,314,000 $ 11,431,000 Cash and cash equivalents $ 6,214,000 $ 11,431,000 Restricted cash 100,000 - Total cash and restricted cash $ 6,314,000 $ 11,431,000 See accompanying notes to the consolidated financial statements. 35 DSS, INC. AND SUBSIDIARIES NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS 1. DESCRIPTION OF BUSINESS The Company, incorporated in the state of New York in May 1984 has conducted business in the name of Document Security Systems, Inc. On September 16, 2021, the board of directors approved an agreement and plan of merger with a wholly owned subsidiary, DSS, Inc. (a New York corporation, incorporated in August 2020), for the sole purpose of effecting a name change from Document Security Systems, Inc. to DSS, Inc. This change became effective on September 30, 2021. DSS, Inc. maintained the same trading symbol “DSS”. DSS, Inc. (together with its consolidated subsidiaries, referred to herein as “DSS,” “we,” “us,” “our” or the “Company”) currently operates four (4) distinct business lines with operations and locations around the globe. These business lines are: (1) Product Packaging, (2) Biotechnology, (3) Commercial Lending, (4) Securities and Investment Management. Our divisions, their business lines, subsidiaries, and operating territories: (1) Our Product Packaging line is led by Premier Packaging Corporation, Inc. (“Premier”), a New York corporation. Premier operates in the paper board and fiber based folding carton, consumer product packaging, and document security printing markets. It markets, manufactures, and sells sophisticated custom folding cartons, mailers, photo sleeves and complex 3-dimensional direct mail solutions. Premier is currently located in its new facility in Rochester, NY, and primarily serves the US market. (2) The Biotechnology business line was created to invest in or acquire companies in the BioHealth and BioMedical fields, including businesses focused on the advancement of drug discovery and prevention, inhibition, and treatment of neurological, oncological, and immune related diseases. This division is also targeting unmet, urgent medical needs, and is developing open-air defense initiatives, which curb transmission of air-borne infectious diseases, such as tuberculosis and influenza. (3) Our Commercial Lending business division, driven by American Pacific Financial (“APF”), provides financing solutions including commercial business lines of credit, land development financing, inventory financing, equipment financing, and third-party loan servicing (4) Securities and Investment Management was established to develop and/or acquire assets in the securities trading or management arena, and to pursue, among other product and service lines, broker dealers, and mutual funds management. Also in this segment is the Company’s real estate investment trusts (“REIT”), organized for the purposes of acquiring hospitals and other acute or post-acute care centers from leading clinical operators with dominant market share in secondary and tertiary markets, and leasing each property to a single operator under a triple-net lease. the REIT was formed to originate, acquire, and lease a credit-centric portfolio of licensed medical real estate. On June 21, 2025, Impact BioMedical Inc. (“Impact”), Dr Ashleys Limited, a Cayman Islands exempted company limited by shares (“PubCo”), Dr Ashleys Nevada Sub, Inc., a Nevada corporation and wholly-owned subsidiary of PubCo (“Merger Sub”), Dr Ashleys Bio Labs Limited, a Cayman Islands exempted company limited by shares (“Dr Ashleys Cayman”), and Kanans Visvanats (a.k.a. Kannan Vishwanatth), a Latvian national, solely in his capacity as the sole shareholder of Dr Ashleys (“Dr Ashleys Shareholder”) entered into a Merger and Share Exchange Agreement (the “Merger Agreement”). Pursuant to the Merger Agreement and subject to the terms and conditions set forth therein, (i) Merger Sub shall be merged with and into Impact with Impact being the surviving entity (the “Merger”), and (ii) simultaneous with or immediately following the Merger, PubCo shall acquire all of the issued and outstanding ordinary shares of Dr Ashleys Cayman from the Dr Ashleys Shareholder (the “Share Exchange”). The closing date of the transaction is uncertain as of March 15, 2026, due to the pending approval from regulatory authorities. Both parties agreed to extend the closing date to July 1, 2026. Management will continue evaluating the status of this deal. 36 2. BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation - The accompanying consolidated financial statements have been prepared in conformity with U.S. generally accepted accounting principles (U.S. GAAP). Any reference in these notes to applicable guidance is meant to refer to U.S. GAAP as found in the Accounting Standards Codification (ASC) and Accounting Standards Updates (ASU) of the Financial Accounting Standards Board (FASB). Principles of Consolidation – The consolidated financial statements include the accounts of DSS and its subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation. Use of Estimates – The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States requires the Company to make estimates and assumptions that affect the amounts reported and disclosed in the financial statements and the accompanying notes. Actual results could differ materially from these estimates. On an ongoing basis, the Company evaluates its estimates, including those related to the accounts receivable, convertible notes receivable, inventory, fair values of investments, intangible assets and goodwill, useful lives of intangible assets and property and equipment, the impairment of long-lived assets, fair values of options and warrants to purchase the Company’s common stock, preferred stock, deferred revenue, and income taxes, among others. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Reclassifications - Certain prior period amounts have been reclassified to conform to the current period presentation. Such reclassifications had no effect on previously reported net income, cash flows, total assets, total liabilities, or total stockholders’ equity. Revision of prior period financial statements - During 2025, the Company identified and corrected immaterial classification errors in our previously reported Consolidated balance sheet as of December 31, 2024. The correction of these error between current and noncurrent assets resulted in an increase in the current asset line item referred to as “Investments in trading securities” and a decrease in the noncurrent line-item referred to as Investment in equity securities by $2,878,000, respectively, from the previously reported amounts of $0 to $2,878,000, and $9,211,000 to $6,333,000, respectively. In addition, the Company reclassified $ 298,00 from additional paid-in capital to noncontrolling interests within equity to correct an immaterial prior-period classification error The Company also reclassed $ 5,008,000 million from Current portion of long-term debt on assets-held-for sale, net to Accrued interest on long-term debt. This revision did not affect total current liabilities or total liabilities. Additionally, the Company identified certain immaterial errors in the classification of amounts reported in the consolidated statement of cash flows for the year ended December 31, 2024. Specifically, $ 3,327,000 of cash outflows related to purchases of marketable securities, which were previously presented within investing activities, should have been presented within operating activities, and $ 3,648,000 related to accrued interest, which was previously presented within financing activities as part of borrowings of long-term debt, should have been presented within operating activities. As a result of the revision, net cash used in operating activities for the year ended December 31, 2024 decreased from $ 9,082,000 to $ 8,761,000 , net cash provided by investing activities increased from $ 8,811,000 to $ 12,138,000 , and net cash provided by financing activities decreased from $ 5,087,000 to $ 1,439,000 . The Company assessed the materiality of these change in presentation on prior period financial statements in accordance with SEC Staff Accounting Bulletin No. 99, “Materiality,” (ASC Topic 250, Accounting Changes and Error Corrections). Based on this assessment, the Company concluded that this classification error corrections in its Consolidated balance sheet and Consolidated statement of cash flows are not material to any previously presented financial statements based upon overall considerations of both quantitative and qualitative factors. The correction had no effect on any previously reported amounts in our consolidated financial statements as of and for the year ended December 31, 2024 other than those previously mentioned. Cash Equivalents – All highly liquid investments with maturities of three months or less at the date of purchase are classified as cash equivalents. Amounts included in cash equivalents in the accompanying consolidated balance sheets are money market funds whose adjusted costs approximate fair value. Restricted cash - Restricted cash consists of deposits and other cash balances that are restricted as to withdrawal or use under the terms of certain contractual arrangements. These amounts are generally maintained as collateral for letters of credit, lease-related security deposits, or other business requirements. The Company classifies restricted cash as a current assets on noncurrent asset on the Consolidated balance sheets based on when the applicable restrictions are expected to lapse. For purposes of the consolidated statements of cash flows, cash, cash equivalents, and restricted cash are presented in total Accounts Receivable – The Company extends credit to its customers in the normal course of business. The Company performs ongoing credit evaluations and generally does not require collateral. Payment terms are generally 30 days but up to net 120 for certain customers. The Company carries its trade accounts receivable at invoice amounts and its rent receivables at contract amounts, less an allowance for credit losses. On a periodic basis, the Company evaluates its accounts receivable and establishes an allowance for credit losses based upon management’s estimates that include a review of the history of past write-offs and collections and an analysis of current credit conditions. In estimating expected losses in the accounts receivable portfolio, customer-specific financial data and macro-economic assumptions are utilized to project losses over a reasonable and supportable forecast period. Assumptions and judgment are applied to measure amounts and timing of expected future cash flows, collateral values and other factors used to determine the customers’ abilities to pay. At December 31, 2025, and December 31, 2024 the Company established a reserve for credit losses of approximately $ 1,014,000 and $ 1,613,000 , respectively. The Company does not accrue interest on past due accounts receivable. Accounts receivable, net was $ 2,254,000 , and $ 3,068,000 for December 31, 2025, and December 31, 2024, respectively. Concentration of Credit Risk - The Company maintains its cash in bank deposit accounts, which at times may exceed federally insured limits. The Company believes it is not exposed to any significant credit risk because of any non-performance by the financial institutions. As of December 31, 2025, one customer accounted for approximately 29 % of our consolidated revenue. As of December 31, 2024, one customer accounted for approximately 22 % of our consolidated revenue and second customer accounted for approximately 13 % of our consolidated revenue Notes receivable, unearned interest, and related recognition - The Company records all future payments of principal and interest on notes as notes receivable, which are then offset by the amount of any related unearned interest income. For financial statement purposes, the Company reports the net investment in the notes receivable on the consolidated balance sheet as current or long-term based on the maturity date of the underlying notes. Such net investment is comprised of the amount advanced on the loans, adjusting for net deferred loan fees or costs incurred at origination, amounts allocated to warrants received upon origination, and any payments received in advance. The unearned interest is recognized over the term of the notes and the income portion of each note payment is calculated so as to generate a constant rate of return on the net balance outstanding. Net deferred loan fees or costs, together with discounts recognized in connection with warrants acquired at origination, are accreted as an adjustment to yield over the term of the loan. Allowance For Loans And Lease Losses - ASC Topic 326 which requires an allowance for credit losses to be deducted from the amortized cost basis of financial assets to present the net carrying value at the amount that is expected to be collected over the contractual term of the asset considering relevant information about past events, current conditions, and reasonable and supportable forecasts that affect the collectability of the reported amount. In estimating expected losses in the loan portfolio, borrower-specific financial data and macro-economic assumptions are utilized to project losses over a reasonable and supportable forecast period. Assumptions and judgment are applied to measure amounts and timing of expected future cash flows, collateral values and other factors used to determine the borrowers’ abilities to repay obligations. After the forecast period, the Company utilizes longer-term historical loss experience to estimate losses over the remaining contractual life of the loans. At December 31, 2025, and December 31, 2024, the Company established a reserve for credit losses of approximately $ 7,478,000 , $ 9,406,000 , respectively Investments – Investments in equity securities with a readily determinable fair value, not accounted for under the equity method, are recorded at fair value with unrealized gains and losses included in earnings. For other equity securities without a readily determinable fair value, the investment is recorded at cost, less any impairment, plus or minus adjustments related to observable transactions for the same or similar securities, with unrealized gains and losses included in earnings. For equity method investments, the Company regularly reviews its investments to determine whether there is a decline in fair value below book value. If there is a decline that is other-than-temporary, the investment is written down to fair value. See Note 8 for further discussion on investments. 37 Fair Value of Financial Instruments - Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The Fair Value Measurement Topic of the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) establishes a three-tier fair value hierarchy which prioritizes the inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). These tiers include: ● Level 1, defined as observable inputs such as quoted prices for identical instruments in active markets. ● Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and ● Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable. The carrying amounts reported in the consolidated balance sheet of cash and cash equivalents, accounts receivable, prepaids, accounts payable and accrued expenses approximate fair value because of the immediate or short-term maturity of these financial instruments. Marketable securities classify as a Level 1 fair value financial instrument. The fair value of notes receivable approximates their carrying value as the stated or discounted rates of the notes do not reflect recent market conditions. The fair value of revolving credit lines notes payable and long-term debt approximates their carrying value as the stated or discounted rates of the debt reflect recent market conditions. The fair value of investments where the fair value is not considered readily determinable, are carried at cost. Inventory – Inventories consist primarily of paper, pre-printed security paper, paperboard, fully prepared packaging, air filtration systems, and health and beauty products which and are stated at the lower of cost or net realizable value on the first-in, first-out (“FIFO”) method. Packaging work-in-process and finished goods included the cost of materials, direct labor and overhead. At the closing of each reporting period, the Company evaluates its inventory in order to adjust the inventory balance for obsolete and slow-moving items. An allowance for obsolescence of approximately $ 53,000 and $ 180,000 associated with the inventory at our Premier subsidiary for December 31, 2025 and 2024, respectively. Write- downs and write-offs are charged to Cost of revenue. During 2025, the Company wrote off approximately $ 419,000 of its Celios completed units of its air purification inventory, as management believes those inventory will not materially generate future sales. Property, Plant and Equipment – Property, plant and equipment are recorded at cost. Depreciation is computed using the straight-line method over the estimated useful lives or lease period of the assets whichever is shorter. Expenditures for renewals and betterments are capitalized. Expenditures for minor items, repairs and maintenance are charged to operations as incurred. Any gain or loss upon sale or retirement due to obsolescence is reflected in the operating results in the period the event takes place. Investments in real estate, net – Acquisition of assets are recorded at their relative fair value based on total accumulated costs of the acquisition. Direct acquisition-related costs are capitalized as a component of the acquired assets. This includes all costs related to finding, analyzing and negotiating a transaction. The allocation of the purchase price is an area that requires judgment and significant estimates. Tangible and intangible assets include land, building and improvements, furniture, fixtures and equipment, acquired above market and below market leases, in-place lease value (if applicable). Acquisition date fair values of assets and assumed liabilities are determined based on replacement costs, appraised values, and estimated fair values using methods similar to those used by independent appraisers and that use appropriate discount and/or capitalization rates and available market information. Depreciation and amortization is computed using the straight-line method over the estimated useful lives of the assets. Depreciation, amortization, cost to maintain and secure the buildings as well as interest incurred on the loans to procure the real estate are included in Cost of revenue on the accompanying Condensed consolidated statement of operations. During 2023, the land and buildings related to AMRE LifeCare and AMRE Winter Haven were reclassified to Assets held for sale. During 2024, the land and buildings related to AMRE Shelton were reclassified to Assets held for sale. As of December 31, 2025, circumstances around the sale of these properties have changed and the Company does not believe the sale of these properties will be finalized within the 12 months from the filing of these quarterly financial statements and have reclassified these assets to Investment in real estate, net and will begin to depreciate these assets prospectively. The Company’s policy is to obtain an independent third-party valuation for each major project in the United States as part of our assessment of identifying potential triggering events for impairment. Management may use the market comparison method to value the investments. In addition to the annual assessment of potential triggering events in accordance with ASC 360 – Property Plant and Equipment (“ASC 360”), the Company applies a fair value-based impairment test to the net book value assets on an annual basis and on an interim basis if certain events or circumstances indicate that an impairment loss may have occurred. The Company recorded impairment on for the amount of $ 2,240,000 and $ 7,288,000 for the year ended December 31, 2025, and 2024, respectively. Leases - ASC 842 requires recognition of leases on the consolidated balance sheets as right-of-use (“ROU”) assets and lease liabilities. ROU assets represent the Company’s right to use underlying assets for the lease terms and lease liabilities represent the Company’s obligation to make lease payments arising from the leases. Operating lease ROU assets and operating lease liabilities are recognized based on the present value and future minimum lease payments over the lease term at commencement date. As the Company’s leases do not provide an implicit rate, the Company used its estimated incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. A number of the lease agreements contain options to renew and options to terminate the leases early. The lease term used to calculate ROU assets and lease liabilities only includes renewal and termination options that are deemed reasonably certain to be exercised. 38 The Company recognized lease liabilities, with corresponding ROU assets, based on the present value of unpaid lease payments for existing operating leases longer than twelve months. Operating lease cost is recognized as a single lease cost on a straight-line basis over the lease term and is recorded in selling, general and administrative expenses. Variable lease payments for common area maintenance, property taxes and other operating expenses are recognized as expense in the period incurred. The Company has elected to separate lease and non-lease components for all property leases for the purposes of calculating ROU assets and lease liabilities. Impairment of Long-Lived Assets and Goodwill - The Company monitors the carrying value of long-lived assets for potential impairment and tests the recoverability of such assets whenever events or changes in circumstances indicate that the carrying amounts may not be recoverable. If a change in circumstance occurs, the Company performs a test of recoverability by comparing the carrying value of the asset or asset group to its undiscounted expected future cash flows. If cash flows cannot be separately and independently identified for a single asset, the Company will determine whether impairment has occurred for the group of assets for which the Company can identify the projected cash flows. If the carrying values are in excess of undiscounted expected future cash flows, the Company measures any impairment by comparing the fair value of the asset or asset group to its carrying value. In June 2025, the Company resigned its position as the registered investment advisor (“RIA”) that it assumed in September of 2021 of the American First Mutual Funds and impaired the related asset acquired in September 2021 in the amount of $ 600,000 . Assets held for sale – The Company has several buildings and associated land for sale as of December 31, 2024. These consist of primarily of retail space in Lindon, Utah approximating $ 5,593,000 and the medical facilities associated with AMRE LifeCare of approximately $ 41,541,000 and AMRE Winter Haven of approximately $ 4,396,000 , and $ 65,000 of other assets. As of December 31, 2024, the balance associated with AMRE LifeCare was approximately $ 34,450,000 , AMRE Shelton was approximately $ 6,313,000 and AMRE Winter Haven was approximately $ 4,396,000 . As of December 31, 2025, circumstances around the sale of these properties have changed and the Company does not believe the sale of these properties will be finalized within the 12 months from the filing of these quarterly financial statements and have reclassified these assets to Investment in real estate, net and will begin to depreciate these assets prospectively. Goodwill – Goodwill is the excess of cost of an acquired entity over the fair value of amounts assigned to assets acquired and liabilities assumed in a business combination. Goodwill is subject to impairment testing at least annually and will be tested for impairment between annual tests if an event occurs or circumstances change that would indicate the carrying amount may be impaired. FASB ASC Topic 350 provides an entity with the option to first assess qualitative factors to determine whether the existence of events or circumstances leads to a determination that it is more likely than not that the fair value of a reporting unit is less than its carrying amount. If, after completing the assessment, it is determined that it is more likely than not that the fair value of a reporting unit is less than its carrying value, the Company will proceed to a quantitative test. The Company may also elect to perform a quantitative test instead of a qualitative test for any or all of our reporting units. The test compares the fair value of an entity’s reporting units to the carrying value of those reporting units. This quantitative test requires various judgments and estimates. The Company estimates the fair value of the reporting unit using a market approach in combination with a discounted operating cash flow approach. Impairment of goodwill is measured as the excess of the carrying amount of goodwill over the fair values of recognized and unrecognized assets and liabilities of the reporting unit. The Company performed its annual goodwill impairment test as of December 31, 2025, and no impairment was deemed necessary for the goodwill associated with Premier Packaging Company of approximately $ 1,769,000 . The Company performed a similar test for Impact BioMedical during 2024 and determined impairment was necessary. Projected cash flows, evaluated using a 26.3% discount rate and 3.0% terminal growth, indicated equity fair value far below the carrying amount, driven by limited historical revenues and sustained operating losses. Additional working-capital and related-party debt balance considerations further reduced equity value in the analysis. Taken together, these factors constituted triggering events and supported recording a goodwill impairment in the amount of $25,093,000 as of December 31, 2024. Intangible Assets - The estimated fair values of acquired intangibles are generally determined based upon future economic benefits such as earnings and cash flows. Acquired identifiable intangible assets are recorded at fair value and are amortized over their estimated useful lives. Acquired intangible assets with an indefinite life are not amortized but are reviewed for impairment at least annually or more frequently whenever events or changes in circumstances indicate that the carrying amounts of those assets are below their estimated fair values. Impairment is tested under ASC 350. At December 31, 2024, The Company impaired approximately $ 7,418,000 associated with intangible assets for AMRE Lifecare and AMRE Winter Haven. There was no impairment of intangible assets deemed necessary for 2025. Margin loan payable - The Company utilizes margin loans to finance certain investments in marketable securities. These loans are recorded as a liability at the principal amount borrowed and are classified as other current liabilities on the Consolidated Balance Sheets, as they are generally due on demand. Interest expense is recognized as incurred within Interest expense on the Consolidated statement of operations. Marketable securities purchased on margin are recorded at fair value within Investments in marketable securities, current on the Consolidated balance sheets. As of December 31, 2025, the Company has a margin loan agreement with Apex Clearing Corp., which is used to finance additional investments in equity securities. The margin loan bears an annual interest rate of 8.95 % at December 31, 2025. The loan is collateralized by the securities purchased. As of December 31, 2025, and 2024 the Company had an outstanding margin loan balance of $ 3,569,000 and $ 3,295,000 , respectively, and is included in Other current liabilities on the Consolidated balance sheet. These securities serve as collateral for the margin loan; under the terms of the agreement, the Company is required to maintain a minimum equity balance. If the fair value of the collateral falls below this level, the Company may be required to deposit additional cash or sell securities to meet a margin call Convertible Promissory Note -The Company accounts for convertible promissory notes in accordance with ASU 2020-06, and evaluates embedded features under ASC 815, Derivatives and Hedging . Upon issuance, convertible notes are recorded at their principal amount, net of any original issue discount (“OID”) and debt issuance costs. OID and issuance costs are presented as a direct deduction from the carrying amount of the debt and are amortized to interest expense using the effective interest method over the contractual term (ASC 835-30). The Company assesses all terms and features of its convertible notes, including conversion options, redemption provisions, make-whole or down-round adjustments, and default put/call rights, to determine whether any embedded features shall be bifurcated and accounted for as derivatives at fair value with changes in fair value recognized in earnings (ASC 815 and ASC 820), or whether the convertible note instrument could be qualified for simplified accounting per ASU 2020-06 and recorded at amortized cost as liability. Convertible notes are classified as current or noncurrent liabilities based on contractual maturity and the Company’s intent and ability to settle the obligation within twelve months of the balance sheet date. Accrued interest and amortization of discounts and issuance costs are included in interest and amortization expense, respectively. For diluted earnings per share, the Company applies the if-converted method to its convertible instruments in accordance with ASU 2020-06 (ASC 260). Revenue - The Company recognizes its revenue based on when the title passes to the customer or when the service is completed and accepted by the customer. Revenue is measured as the amount of consideration the Company expects to receive in exchange for shipped product or service provided. Sales and other taxes billed and collected from customers are excluded from revenue. The Company recognizes rental income associated with its REIT, net of amortization of favorable/unfavorable lease terms relative to market and includes rental abatements and contractual fixed increases attributable to operating leases, where collection has been considered probable, on a straight-line basis over the term of the related lease. Commission revenues are generated when the Company buys and sells bond and equity securities on behalf of its customers. Each time a customer enters into a buy or sell transaction, the Company recognizes a commission. Commissions and related clearing expenses are recorded on the trade date. The Company recognizes net investment income from its investment banking line of business as interest and management fees related to loans managed for third parties owed to the Company occurs. 39 As of December 31, 2025 and 2024, the Company had no unsatisfied performance obligations for contracts with an original expected duration of greater than one year. Pursuant to Topic 606, the Company has applied the practical expedient with respect to disclosure of the deferral and future expected timing of revenue recognition for transaction price allocated to remaining performance obligations. The Company elected the practical expedient allowing it to not recognize as a contract asset the commission paid to its salesforce on the sale of its products as an incremental cost of obtaining a contract with a customer but rather recognize such commission as expense when incurred as the amortization period of the asset that the Company would have otherwise recognized is one year or less. Costs of revenue - Costs of revenue includes all direct cost of the Company’s packaging, commercial and security printing sales, primarily, paper, inks, dies, and other consumables, and direct labor, transportation, amortization, deprecation, and manufacturing facility costs. In addition, this category includes all direct costs associated with the manufacturing and procurement of the products sold in the Company’s technology sales, services and licensing including hardware and software that is resold, third-party fees, and fees paid to inventors or others as a result of technology licenses or settlements, if any. Cost of revenue for our REIT line of business includes all direct cost associated with the maintenance and upkeep of the related facilities, depreciation, amortization and the costs to acquire the facilities. Our Commercial Lending operating segment has costs of revenue associated with the impairment of notes receivable for those amounts at risk of collection. Costs of revenue do not include expenses related to product development, integration, and support. These costs are included in research and development, which is a component of selling, general and administrative expenses on the consolidated statement of operations. Legal costs are included in selling, general and administrative. Shipping and Handling Costs - Costs incurred by the Company related to shipping and handling are included in cost of revenue. Amounts charged to customers pertaining to these costs are reflected as revenue. Share-Based Payments - Compensation cost for stock awards are measured at fair value and the Company recognizes compensation expense over the service period for which awards are expected to vest. The Company uses the Black-Scholes-Merton option pricing model for determining the estimated fair value for stock-based awards. The Black-Scholes-Merton model requires the use of subjective assumptions which determine the fair value of stock-based awards, including the option’s expected term and the price volatility of the underlying stock. For equity instruments issued to consultants and vendors in exchange for goods and services the Company determines the measurement date for the fair value of the equity instruments issued at the earlier of (i) the date at which a commitment for performance by the consultant or vendor is reached or (ii) the date at which the consultant or vendor’s performance is complete. In the case of equity instruments issued to consultants, the fair value of the equity instrument is recognized over the term of the consulting agreement. Sales Commissions - Sales commissions are expensed as incurred for contracts with an expected duration of one year or less. A significant portion of the Company’s sales commissions expense is generated from its direct marketing line of business. These commissions are based on current month shipments and are paid one month in arrears. There were no sales commissions capitalized as of December 31, 2025 or 2024. Contingent Legal Expenses - Contingent legal fees are expensed in the consolidated statements of operations in the period that the related revenues are recognized. In instances where there are no recoveries from potential infringers, no contingent legal fees are paid; however, the Company may be liable for certain out of pocket legal costs incurred pursuant to the underlying legal services agreement that will be paid out from the proceeds from settlements or licenses that arise pursuant to an enforcement action, which will be expensed as legal fees in the period in which the payment of such fees is probable. Any unamortized patent acquisition costs will be expensed in the period a conclusion is reached in an enforcement action that does not yield future royalties potential. Research and Development - Research and development costs are expensed as incurred. Research and development costs consist primarily of third-party research costs and consulting costs. The Company recognized costs of approximately $ 340,000 and $ 278,000 in 2025 and 2024, respectively. Income Taxes - The Company recognizes estimated income taxes payable or refundable on income tax returns for the current year and for the estimated future tax effect attributable to temporary differences and carry-forwards. Measurement of deferred income items is based on enacted tax laws including tax rates, with the measurement of deferred income tax assets being reduced by available tax benefits not expected to be realized. We recognize penalties and accrued interest related to unrecognized tax benefits in income tax expense. Loss Per Common Share - The Company presents basic and diluted (loss) earnings per share. Basic (loss) earnings per share reflect the actual weighted average of shares issued and outstanding during the period. Diluted (loss) earnings per share are computed including the number of additional shares from outstanding warrants, stock options and preferred stock that would have been outstanding if dilutive potential shares had been issued and is calculated utilizing the treasury stock method. In a loss period, the calculation for basic and diluted (loss) earnings per share is the same, as the impact of potential common shares is anti-dilutive. For the year ended December 31, 2025 and 2024, there were no potential dilutive instruments issued and outstanding. 40 Business Combinations and Acquisitions - Business combinations and non-controlling interests are recorded in accordance with FASB ASC 805 Business Combinations. Under the guidance, the assets and liabilities of the acquired business are recorded at their fair values at the date of acquisition and all acquisition costs are expensed as incurred. The excess of the purchase price over the estimated fair values is recorded as goodwill. If the fair value of the assets acquired exceeds the purchase price and the liabilities assumed, then a gain on acquisition is recorded. The application of business combination accounting requires the use of significant estimates and assumptions. Acquisition of assets are recorded at their relative fair value based on total accumulated costs of the acquisition. Direct acquisition-related costs are expensed as incurred. This includes all costs related to finding, analyzing and negotiating a transaction. The allocation of the purchase price is an area that requires judgment and significant estimates. Tangible and intangible assets include land, building and improvements, furniture, fixtures and equipment, acquired above market and below market leases, in-place lease value (if applicable). Acquisition-date fair values of assets and assumed liabilities are determined based on replacement costs, appraised values, and estimated fair values using methods similar to those used by independent appraisers and that use appropriate discount and/or capitalization rates and available market information. Continuing Operations and Going Concern - The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. This basis of accounting contemplates the recovery of our assets and the satisfaction of liabilities in the normal course of business. These consolidated financial statements do not include any adjustments to the specific amounts and classifications of assets and liabilities, which might be necessary should we be unable to continue as a going concern. While the Company has approximately $ 6.2 million in cash, the Company has incurred operating losses as well as negative cash flows from operating activities over the past two years. Aside from its $ 6.2 million in cash as of December 31, 2025, to continue as a going concern, the Company can generate operating cash through the sale of its $ 6.5 million of marketable securities. To continue as a going concern, Also, historically, the Company has been able to obtain equity via issuance of authorized shares of its common stock currently not issued and/or debt-based financing to meet its working capital needs. In addition, the Company has taken steps, and will continue to take measures, to materially reduce the expenses and cash burn at all corporate and business line levels Recent Accounting Standards - The Financial Accounting Standards Board (FASB) issues various Accounting Standards Updates relating to the treatment and recording of certain accounting transactions. There are several new accounting pronouncements issued by FASB which are not yet effective. Each of these pronouncements, as applicable, has been or will be adopted by the Company. In November 2023, the Financial Accounting Standards Board (“FASB”), issued Accounting Standards Update (“ASU”) 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which improves reportable segment disclosure through enhanced disclosures about significant segment expenses. The amendment is effective for fiscal years beginning after December 15, 2023 and for interim periods within fiscal years beginning after December 15, 2024 and early adoption is permitted. The amendments should be applied retrospectively to all prior periods presented in the financial statements. The Company has adopted the enhanced segment disclosures for the year ended December 31, 2024. The Company reports its segment information to reflect the manner in which the Company’s chief operating decision maker (“CODM”) reviews and assesses performance. The Company’s Interim Chief Executive Officer has responsibilities as the CODM and review and assess the performance of the Company as a whole. The primary financial measures used by the CODM to evaluate performance and allocate resources are net income (loss) and operating income (loss). The CODM uses net income (loss) and operating income (loss) to evaluate the performance of the Company’s ongoing operations and as part of the Company’s internal planning and forecasting processes. Information on Net loss and Operating loss is disclosed in the Condensed Consolidated Statements of Operations. Segment expenses and other segment items are provided to the CODM on the same basis as disclosed in the Condensed Consolidated Statements of Operations. The CODM does not evaluate performance or allocate resources based on segment assets, and therefore such information is not presented in the notes to the financial statements In December 2023, the FASB issued ASU 2023-09, “Improvements to Income Tax Disclosures” which is intended to simplify various aspects related to accounting for income taxes. ASU 2023-09 removes certain exceptions to the general principles in Topic 740 and also clarifies and amends existing guidance to improve consistent application. The amendments in ASU 2023-09 are effective for public business entities for fiscal years beginning after December 15, 2024, including interim periods therein. Early adoption of the standard is permitted, including adoption in interim or annual periods. The adoption of this ASU did not have a material impact on the Consolidated Financial Statements In November 2024, the FASB issued ASU No. 2024-03 (“ASU 2024-03”), Disaggregation of Income Statement Expenses (“DISE”) . ASU 2024-03 requires disaggregated disclosure of income statement expenses for public business entities. ASU 2024-03 does not change the expense captions an entity presents on the face of the income statement; rather, it requires disaggregation of certain expense captions into specified categories in disclosures within the footnotes to the financial statements. As revised by ASU No. 2025-01, Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures, the provisions of ASU 2024-03 are effective for fiscal years beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027, with early adoption permitted. With the exception of expanding disclosures to include more granular income statement expense categories, we do not expect the adoption of ASU 2024-03 to have a material effect on our consolidated financial statements taken as a whole. In November 2024, the FASB issued ASU 2024-04 (“ASU 2024-04”), Debt—Debt with Conversion and Other Options (Subtopic 470-20): Induced Conversions of Convertible Debt Instruments , which clarifies the requirements for determining whether certain settlements of convertible debt instruments should be accounted for as induced conversions or as extinguishments. The amendments in ASU 2024-04 are effective for annual reporting periods beginning after December 15, 2025, and interim reporting periods within those annual reporting periods. Early adoption is permitted for entities that have adopted ASU 2020-06. The Company is currently evaluating the effect of adopting ASU 2024-04 on its consolidated financial statements and related disclosures. The Company does not currently expect the adoption of this standard to have a material impact on its consolidated financial statements. 41 3. INVENTORY Inventory consisted of the following as of December 31: SCHEDULE OF INVENTORY 2025 2024 Finished Goods $ 807,000 $ 1,857,000 Work in Process 498,000 345,000 Raw Materials 746,000 420,000 Inventory Gross $ 2,051,000 $ 2,622,000 Less allowance for obsolescence ( 53,000 ) ( 180,000 ) Inventory Net $ 1,998,000 $ 2,442,000 4. NOTES RECEIVABLE Note 1 On May 14, 2021, DSS Pure Air, Inc. a subsidiary of the Company entered a convertible promissory note (“Note 1”) with Puradigm, Inc. (“Puradigm”), a company registered in the state of Texas. Note 1 has an aggregate principal balance up to $ 5,000,000 , to be funded at the request of Puradigm. Note 1, which incurs interest at a rate of 6.65 % due quarterly, had a maturity date of May 1, 2023 . Note 1 contains an optional conversion clause that allows the Company to convert all, or a portion of all, into newly issued member units of Puradigm with the maximum principal amount equal to 18% of the total equity position of Puradigm at conversion. The outstanding principal and interest as of December 31, 2025 and December 31, 2024, approximated $ 5,544,000 . As of December 31, 2025 and December 31, 2024 this note is in default and the Company has a reserve of $ 5,544,000 against the principal and interest outstanding. Note 2 On October 25, 2021, APF entered into a loan agreement (“Note 2”) with Asili, LLC. (“Asili”), a company registered in the state of Utah. Note 3 has an initial aggregate principal balance up to $ 1,000,000 , to be funded at the request of Asili, with an option to increase the maximum principal borrowing to $ 3,000,000 . Note 2, which incurs interest at a rate of 8.0 % with principal and interest due at the maturity date of October 25, 2022 . This note contains an optional conversion feature allowing APF to convert the outstanding principal to a 10 % membership interest. APF, as holder of Note 2, has the right to elect one member to the Board of Managers. This note is in default and the outstanding principal and interest of approximately $ 884,000 is fully reserved for as of December 31, 2025 and December 31, 2024. Note 3 On January 24, 2022, APF and an individual entered into a promissory note (“Note 3”) in the principal sum of $ 100,000 with interest of 6 %, due annually, and maturing in January 2024 . The outstanding principal and interest at December 31, 2024 approximated $ 17,000 and was included in Current portion of notes receivable on the accompanying consolidate balance sheet. As of December 31, 2025, the outstanding principal and interest approximating $ 18,000 were written-off. 42 Note 4 On March 2, 2022, APF and WUURII Commerce, Inc. (“WUURII”), a corporation organized under the laws of the Republic of Korea entered into a promissory note (“Note 4”). Under the terms of Note 4, APF at its discretion, may lend up to the principal sum of $ 893,000 with an interest rate of 8 %, and matured in March 2024 and was extended to April 2025 , with interest payable quarterly. The outstanding principal and interest at December 31, 2025, and December 31, 2024 is $ 465,000 and $ 468,000 , respectively. This loan is currently in default and as of December 31, 2025 the Company has a reserve of $ 465,000 against the principal and interest outstanding. Note 5 On May 9, 2022, DSS PureAir and Puradigm entered into a promissory note (“Note 5”) in the principal sum of $ 210,000 with interest of 10 %, is due in three quarterly installments beginning on August 9, 2022, with the first two payment consisting of interest only. All unpaid principal and interest are due on February 9, 2023 . This loan is currently in default. The outstanding principal and interest at December 31, 2025 and December 31, 2024 approximates $ 224,000 . This note was fully reserved for as of December 31, 2025 and December 31, 2024. Note 6, related party On August 29, 2022, DSS Financial Management Inc and BMI Capital International LLC. (“BMIC LLC”), a related party, entered into a promissory note (“Note 6”) in the principal sum of $ 100,000 with interest of 8 %, is due in three quarterly installments beginning on September 14, 2022. All unpaid principal and interest was due on August 29, 2025 . The outstanding principal and interest at December 31, 2025, and December 31, 2024 approximated $ 86,000 , and was fully reserved for as of December 31, 2025 and December 31, 2024. DSS owns 24.9 % of the outstanding common shares of BMIC LLC. Note 7, related party On May 8, 2023, DSS Financial Management Inc and BMIC LLC entered into a promissory note (“Note 7”) in the principal sum of $ 102,000 with interest at the prime rate plus 2 % with a maturity date of May 7, 2026 . The outstanding principal and interest at December 31, 2025, and December 31, 2024 approximated $ 110,000 , and was fully reserved for as of December 31, 2025 and December 31, 2024. DSS owns 24.9 % of the outstanding common shares of BMIC LLC. Note 8, related party On July 26, 2022, APF and Value Exchange International, Inc. (“VEII”) entered into a promissory note (“Note 8”) in the principal sum of $ 1,000,000 with interest of 8 % with all unpaid principal and interest due on July 26, 2024 . This note was amended so that all unpaid principal and interest is due July 26, 2025. The outstanding principal and interest as of December 31, 2025 and December 31, 2024 approximates $ 917,000 . This note was fully reserved for as of December 31, 2025 and December 31, 2024. Heng Fai Ambrose Chan, the Chairman of DSS, Inc is also the on the board of directors of VEII. Note 9 On February 19, 2021, Impact BioMedical, Inc, entered into a promissory note with an individual. The Company loaned the principal sum of $ 206,000 , with interest at a rate of 6.5 %, and maturity date of August 19, 2022 later amended to February 19, 2026. Monthly payments are due on the twenty-first day of each month and continuing each month thereafter until February 19, 2026. This note is secured by certain real property situated in Collier County, Florida. The outstanding principal and interest as of December 31, 2025, and December 31, 2024 was approximately $ 198,000 and $ 201,000 , respectively. As of December 31, 2025, approximately $ 198,000 is classified in Current notes receivable. As of December 31, 2024, $ 184,000 is classified in Current notes receivable and the remaining $ 17,000 is classified as Notes receivable on the accompanying consolidated balance sheet. The maturity date is currently being renegotiated. Note 10 On June 27, 2023, Decentralized Sharing Systems, Inc. and Stemtech Corporation (“Stemtech”) entered into a convertible promissory note (“Note 10”) in the principal sum of $ 1,400,000 with a discount of $ 300,000 and interest rate of 10 % and maturity date of September 1, 2024 . The outstanding principal, interest, and associated discount was fully reserved for as of December 31, 2024 and written off as of December 31, 2025 43 Note 11 On March 31, 2023, DSS Biohealth Security, Inc and an individual entered into a promissory note (“Note 11”) in the principal sum of $ 140,000 and interest rate floating daily to Wall Street Journal Prime rate per annum with the total outstanding principal and interest due at the maturity date of March 31, 2025 . As of December 31, 2025 and December 31, 2024, the outstanding principal and interest approximated $ 135,000 . This balance was fully reserved for as of December 31, 2025 and December 31, 2024. Note 12 On August 29, 2024, APF entered into a promissory note (“Note 12”) with WestPark. Note 12 has a principal balance of $ 459,000 . Note 12, which incurs interest at a rate of 10.0 % with principal and interest due at the maturity date of April 27, 2026 . On November 1, 2024, monthly payments of approximately $ 28,000 are due with any unpaid interest and principal due at maturity. As of December 31, 2025, the outstanding principal and interest approximates $ 237,000 , which is classified as Current notes receivable on the accompanying consolidated balance sheet. As of December 31, 2024, the outstanding principal and interest approximates $ 450,000 , of which $ 337,000 is classified as Current notes receivable and the remaining $ 113,000 is classified as Non-current notes receivable on the accompanying consolidated balance sheet. 5. PROVISION FOR CREDIT LOSSES ASC Topic 326 for the measurement of credit losses on financial instruments and other financial assets. That guidance requires an allowance for credit losses to be deducted from the amortized cost basis of financial assets to present the net carrying value that is expected to be collected over the contractual term of the assets considering relevant information about past events, current conditions, and reasonable and supportable forecasts that affect the collectability of the reported amount. The guidance replaced the previous incurred loss model for determining the allowance for credit losses. Accounts receivable are stated at the amount owed by the customer. The Company maintains an allowance for credit losses for accounts receivable and unbilled receivables, based on expected credit losses resulting from the inability of our customers to make required payments. The allowance for credit losses is estimated based on historical experience, current economic conditions and the creditworthiness of customers. Receivables are charged to the allowance when determined to be no longer collectible. The Company regularly monitors and assesses its risk of not collecting amounts owed by customers and records its allowance for credit losses based on the results of this analysis. As of December 31, 2025, we have reviewed the entire loan portfolio as well as all financial assets of the Company for the purpose of evaluating the loan portfolio and the loan balances, including a review of individual and collective portfolio loan quality, loan(s) performance, including past due status and covenant defaults, assessment of the ability of the borrower to repay the loan on the loan terms, whether any loans should be placed on nonaccrual or returned to accrual, any concentrations in any single borrower and/or industry that we might need to further manage, and if any specific or general loan loss reserve should be established for the entire loan portfolio or for any specific loan. We analyzed the loan loss reserve from three basis: general loan portfolio reserves; industry portfolio reserves, and specific loan loss reserves. As of year-ended December 31, 2025 and December 2024, the Company recorded a Loan loss reserve of approximately $ 7,478,000 and $ 9,406,000 , respectively. General Loan Portfolio Reserve - Based upon the review of our loan portfolio, we do not believe that a substantial general loan portfolio reserve is due at this time. However, we do recognize that some inherent risks are in all loan portfolios, thus we recorded a general contingent portfolio reserve of $ 0 and $ 196,000 of the loan portfolio loan balance as of December 31, 2025 and December 31, 2024, respectively. Industry Portfolio Reserves – Given the relatively young loan portfolio and a diversification of the portfolio over several different loan products, the risk is reduced. Accordingly, we have not recorded a discretionary reserve as of December 31, 2025 and December 31, 2024 Specific Loan Reserves - Previously, we had identified credit weaknesses and borrower repayment weakness with Asili, which has a current principal and interest balance of $ 884,000 and have recorded a loan loss reserve for the full balance due the Company as of December 31, 2024. The Company had also previously identified credit weakness in Puradigm and has placed a reserve approximating $ 5,768,000 against the outstanding principal and interest as of December 31, 2024 of their two loans. Previously, the Company identified credit weakness in Stemtech and has placed a reserve approximating $ 1,045,000 against the outstanding principal and interest as of December 31, 2024. During the first quarter of 2024, the Company identified credit weakness in VEII and an individual and has placed a reserve approximating $ 959,000 against the outstanding principal and interest as of March 31, 2024. There has been no change to this amount. Also, during the first quarter of 2024, the Company identified credit weakness in BMIC, a related party, and has placed a reserve approximating $ 211,000 against the outstanding principal and interest as of March 31, 2024, later adjusted to $ 196,000 as of December 31, 2024. The Company identified credit weakness with WUURII and has placed a $ 234,000 reserve against the outstanding principal and interest as of December 31, 2024 and reserved for the remaining outstanding balance of approximately $ 233,000 as of December 31, 2025. The Company has also identified credit weakness with an individual and has placed a $ 135,000 reserve against the outstanding principal and interest as of December 31, 2024, and reserved for an approximate $ 17,000 against the outstanding principal and interest for another individual as of December 31, 2025. No additional reserves were deemed necessary as of December 31, 2025. The following table identifies the loan loss reserve for the period ending December 31: SCHEDULE OF LOAN LOSS RESERVE 2025 2024 General Loan Portfolio Reserve $ - $ 196,000 Specific Loan Reserves 7,478,000 9,210,000 Total $ 7,478,000 $ 9,406,000 44 Changes in the allowance for credit losses and loan loss reserve were as follows: SCHEDULE OF ALLOWANCE FOR DOUBTFUL ACCOUNTS AND LOAN LOSS RESERVE Allowance for credit losses Loan loss reserve Total Balance at December 31, 2024 $ 1,613,000 $ 9,406,000 $ 11,019,000 Credit loss expense - 20,000 20,000 Write-offs - ( 1,948,000 ) ( 1,948,000 ) Recoveries ( 600,000 ) - ( 600,000 ) Balance at December 31, 2025 $ 1,013,000 $ 7,478,000 $ 8,491,000 6. FINANCIAL INSTRUMENTS Cash, Cash Equivalents and Marketable Securities The following tables show the Company’s cash and marketable securities by significant investment category as of December 31: SCHEDULE OF CASH AND MARKETABLE SECURITIES BY SIGNIFICANT INVESTMENT CATEGORY 2025 Cost Unrealized Gain/(Loss) Fair Value Cash and Cash Equivalents Marketable Securities Cash $ 4,981,000 $ - $ 4,981,000 $ 4,981,000 $ - Restricted Cash 100,000 - 100,000 100,000 - Level 1 Money Market Funds 1,233,000 - 1,233,000 1,233,000 - Marketable Securities 26,383,000 ( 17,172,000 ) $ 9,211,000 - 9,211,000 Total $ 32,697,000 $ ( 17,172,000 ) $ 15,525,000 $ 6,314,000 $ 9,211,000 2024 Cost Unrealized Gain/(Loss) Fair Value Cash and Cash Equivalents Marketable Securities Cash $ 11,351,000 $ - $ 11,351,000 $ 11,351,000 $ - Level 1 Money Market Funds 62,000 - $ 62,000 62,000 - Marketable Securities 25,933,000 ( 16,722,000 ) $ 9,211,000 - 9,211,000 Total $ 37,364,000 $ ( 16,722,000 ) $ 20,642,000 $ 11,413,000 $ 9,211,000 The following tables shows the Company’s net unrealized (loss) gain recognized during the year on marketable securities as of December 31: SCHEDULE OF NET UNREALIZED (LOSS) GAIN RECOGNIZED ON MARKETABLE SECURITIES 2025 2024 Net gains (losses) recognized during the year on marketable securities $ ( 807,000 ) $ ( 856,000 ) Less: Net gains (losses) realized during the year on marketable securities sold during the period ( 666,000 ) ( 113,000 ) Net unrealized gain (loss) recognized during the reporting year on marketable securities still held at the reporting date $ ( 141,000 ) $ ( 743,000 ) The Company typically invests with the primary objective of minimizing the potential risk of principal loss. The Company’s investment policy generally requires securities to be investment grade and limits the amount of credit exposure to any one issuer. Fair values were determined for each individual security in the investment portfolio. 7. DISPOSAL OF ASSETS On June 13, 2024, the Company sold its retail space in Lindon, Utah for the sales price, net of expenses, of approximately $ 5,758,000 . The associated asset was previously classified as Held for sale in the amount of $ 5,593,000 , resulting in a gain on the sale of approximately $ 165,000 . On March 27, 2025, the Company finalized the sale of its Plano, Tx. Facility for a gross sales price of $ 9,500,000 . The associated asset was previously classified as held for sale in the amount of $ 9,750,000 , resulting in a loss on the sale of approximately $ 727,000 after related expenses. On December 17, 2025 AMRE Winter Haven, LLC., a majority owned subsidiary of the Company, sold its property located in Winter Haven FL. The contract price of $ 4,600,000 . The carrying value of the asset was approximately $ 4,324,000 , resulting in a loss on the sale of property of approximately $ 292,000 after payment of related expenses. On December 22, 2025 AMRE Lifecare, LLC., a majority owned subsidiary of the Company, sold its property located in Fort Worth TX. The contract price of $ 3,100,000 . The carrying value of the asset was approximately $ 11,406,000 , resulting in a loss on the sale of property of approximately $ 8,591,000 after payment of related expenses. 45 8. INVESTMENTS Alset International Limited , related party The Company owns 127,179,291 shares or approximately 4 % of the outstanding shares of Alset International Limited (“Alset Intl”), a company incorporated in Singapore and publicly listed on the Singapore Exchange Limited. This investment is classified as a marketable security and is classified as Investment in marketable securities, noncurrent on the consolidated balance sheets as the Company has the intent and ability to hold the investments for a period of at least one year. The Chairman of the Company, Mr. Heng Fai Ambrose Chan, is the Executive Director and Chief Executive Officer of Alset Intl. Mr. Chan is also the majority shareholder of Alset Intl as well as the largest shareholder of the Company. The fair value of the marketable security as of December 31, 2025, and December 31, 2024, was approximately $ 2,277,000 and $ 2,518,000 respectively. During the year ended December 31, 2025 and December 31, 2024, the Company recorded unrealized loss on this investment of approximately $ 242,000 and unrealized loss of $ 750,000 , respectively. True Partners Capital Holding Limited The Company owns 81,836,908 shares of True Partners Capital Holding Limited (“True Partners”), a publicly listed company on the Hong Kong Stock Exchange. On February 28, 2022, the Company entered into a Stock Purchase Agreement with Alset EHome International Inc. (“AEI”), pursuant to which AEI has agreed to sell a subsidiary holding 62,336,908 shares of stock of True Partner Capital Holding Limited exchange for 17,570,948 shares of common stock of the Company (the “DSS Shares”). The Company’s Executive Chairman and a significant stockholder, Heng Fai Ambrose Chan is the Chairman, Chief Executive Officer and largest shareholder of AEI. Further, on February 20, 2025, the Company acquired an additional 19,500,000 shares of True Partners. The fair value of the marketable security as of December 31, 2025 and December 31, 2024, was approximately $ 4,206,000 and $ 3,815,000 , respectively. During the year ended December 31, 2025 and December 31, 2024, the Company recorded unrealized loss on this investment of approximately $ 609,000 and unrealized loss of $ 590,000 , respectively. West Park Capital, Inc. On December 30, 2020, the Company signed a binding letter of intent with West Park Capital, Inc (“West Park”) and Century TBD Holdings, LLC (“TBD”) where the parties agreed to prepare a note and stock exchange agreement whereby DSS will assign the TBD Note to West Park and West Park shall issue to DSS a stock certificate reflecting 9.2 % of the issued and outstanding shares of West Park. This note and stock exchange agreement was finalized during the first quarter 2022 and valued at approximately $ 500,000 and is included in Investments on the consolidated balance sheet on December 31, 2025 and as of December 31, 2024. No circumstances or events have occurred to indicate the need for an impairment on this asset. For the years ended December 31, 2025 and 2024, no impairment was recorded. BMI Capital International LLC On September 10, 2020, the Company’s wholly owned subsidiary DSS Securities, Inc. entered into membership interest purchase agreement with BMI Financial Group, Inc. a Delaware corporation (“BMIF”) and BMI Capital International LLC, a Texas limited liability company (“BMIC LLC”) whereas DSS Securities, Inc. purchased 14.9 % membership interests in BMIC LLC for $ 100,000 . DSS Securities also had the option to purchase an additional 10 % of the outstanding membership interest which it exercised for $ 100,000 in January of 2021 and increased its ownership to 24.9 %. Upon achieving greater than 20 % ownership in BMIC LLC during the quarter ended September 30, 2021, the Company is currently accounting for this investment under the equity method of accounting per ASC 323. The Company’s portion of net loss in BMIC LLC during the year ended December 31, 2025, approximated $ 16,000 and $ 1,000 for year ended December 31, 2024. No circumstances or events have occurred since the most recent analysis that would indicate the need for an impairment is needed for the years ended December 31, 2025 or 2024. BioMed Technologies Asia Pacific Holdings Limited On December 19, 2020, Impact BioMedical, a wholly owned subsidiary of the Company, entered into a subscription agreement (the “Subscription Agreement”) with BioMed Technologies Asia Pacific Holdings Limited (“BioMed”), a limited liability company incorporated in the British Virgin Islands, pursuant to which the Company agreed to purchase 525 ordinary shares or 4.99 % of BioMed at a purchase price of approximately $ 632,000 . The Subscription Agreement provides, among other things, the Company has the right to appoint a new director to the board of BioMed. With respect to an issuance of shares to a third party by BioMed, the Company will have the right of first refusal to purchase such shares, as well as customary tag-along rights. In connection with the Subscription Agreement, Impact Biomedical entered into an exclusive distribution agreement (the “Distribution Agreement”) with BioMed, to directly market, advertise, promote, distribute, and sell certain BioMed products, which focus on manufacturing natural probiotics, to resellers. This investment is impaired in full at December 31, 2025 as it does not have a readily determined fair value. 46 9. PROPERTY PLANT AND EQUIPMENT AND INVESTMENT IN REAL ESTATE Property, plant and equipment consisted of the following as of December 31: SCHEDULE OF PROPERTY, PLANT AND EQUIPMENT Estimated Useful Life 2025 2024 Machinery and equipment 5 - 10 years $ 10,211,000 $ 9,998,000 Building and improvements 39 years 317,000 317,000 Furniture and fixtures 7 years 441,000 432,000 Software and websites 3 years 240,000 240,000 Total Cost 11,209,000 10,987,000 Less: accumulated depreciation 6,390,000 5,606,000 Property, plant and equipment, net $ 4,819,000 $ 5,381,000 Depreciation expense for the years ended December 31, 2025 and 2024 was $ 803,000 and $ 878,000 respectively. Investment in real estate consisted of the following at December 31: SCHEDULE OF INVESTMENT IN REAL ESTATE Estimated Useful Life 2025 2024 Building and improvements 1 - 30 years $ 11,708,000 $ - Land 5,236,000 - Total Cost 16,944,000 - Less: accumulated depreciation 307,000 - Real estate, net $ 16,637,000 $ - Depreciation expense for the years ended December 31, 2025 and 2024 was $ 698,000 and $ 98,000 respectively. 10. INTANGIBLE ASSETS Intangible assets are comprised of the following as of December 31: SCHEDULE OF INTANGIBLE ASSETS 2025 2024 Useful Life Gross Carrying Amount Accumulated Amortization Write-off Net Carrying Amount Gross Carrying Amount Accumulated Amortization Net Carrying Amount Developed technology assets 20 years $ 22,260,000 $ 5,566,000 - $ 16,694,000 $ 22,260,000 $ 4,453,000 $ 17,807,000 Acquired intangibles customer lists, licenses, non-compete agreements, branding, product formulas, tenant improvements, in-place, favorable and unfavorable leases 1 - 11 years 2,811,000 1,911,000 600,000 300,000 2,895,000 1,863,000 1,032,000 Acquired intangibles patents and patent rights 500,000 500,000 - - 500,000 500,000 - Patent application costs Varied (1) 1,052,000 1,012,000 - 40,000 1,052,000 1,001,000 51,000 $ 26,623,000 $ 8,989,000 $ 600,000 $ 17,034,000 $ 26,707,000 $ 7,817,000 $ 18,890,000 (1) Patent application costs are amortized over their expected useful life which is generally the remaining legal life of the patent. As of December 31, 2025, the weighted average remaining useful life of these assets in service was approximately .7 years 47 Amounts amortized for the year ended December 31, 2025 and 2024 was approximately $ 1,140,000 and $ 1,361,000 , respectively. Expected amortization for each of the five succeeding fiscal years is as follows: SCHEDULE OF ESTIMATED FUTURE AMORTIZATION OF INTANGIBLE ASSETS Year Amount 2026 $ 1,138,000 2027 $ 1,137,000 2028 $ 1,130,000 2029 $ 1,130,000 2030 $ 1,130,000 thereafter $ 11,369,000 11. ACCRUED EXPENSES AND DEFERRED REVENUE Accrued expenses and deferred revenue consist of the following for the year ended December 31: SUMMARY OF ACCRUED EXPENSES AND DEFERRED REVENUE 2025 2024 Customer deposits $ 71,000 $ 86,000 Deferred revenue 5,000 120,000 Accrued wages 520,000 546,000 Accrued expenses 1,119,000 1,890,000 Sales tax payable 10,000 9,000 Accrued expenses and deferred revenue $ 1,725,000 $ 2,651,000 12. SHORT TERM AND LONG-TERM DEBT Promissory Notes - On May 20, 2021, Premier Packaging entered into master loan and security agreement (“BOA Note”) with Bank of America, N.A. (“BOA”) to secure financing approximating $ 3,710,000 to purchase a new Heidelberg XL 106-7+L printing press. The aggregate principal balance outstanding under the BOA Note shall bear interest at a variable rate on or before the loan closing. As of December 31, 2025, and December 31, 2024, the outstanding principal on the BOA Note was $ 1,916,000 and $ 2,436,000 , respectively and had an interest rate of 4.63 %. As of December 31, 2025, $ 544,000 was included in the current portion of long-term debt, net, and the remaining balance of approximately $ 1,372,000 recorded as long-term debt. As of December 31, 2024, $ 520,000 was included in the current portion of long-term debt, net, and the remaining balance of approximately $ 1,916,000 recorded as long-term debt. Interest expense for the years ended December 31, 2025 and 2024 approximated $ 102,000 and $ 125,000 , respectively. The BOA Note contains certain covenants that are analyzed annually. As of December 31, 2025, Premier is in compliance with these covenants. 48 On August 1, 2021, AMRE Shelton, LLC., (“AMRE Shelton”) a subsidiary of AMRE, entered into a loan agreement (“Shelton Agreement”) with Patriot Bank, N.A. (“Patriot Bank”) in an amount up to $ 6,155,000 , with the amount financed approximating $ 5,105,000 . The Shelton Agreement contains monthly payments of principal and an initial interest of 4.25 %. The interest will be adjusted commencing on July 1, 2026 and continuing for the next succeeding 5-year period shall be determined one month prior to the change date and shall be an interest rate equal to two hundred fifty (250) basis points above the Federal Home Loan Bank Boston 5-Year/25-Year amortizing advance rate, but in no event less than 4.25 % for the term of 120 months with a balloon payment approximating $ 2,829,000 due at term end. The affective interest rate at December 31, 2022 was 4.25 %. The funds borrowed were used to purchase a 40,000 square foot, 2.0 story, Class A+ multi-tenant medical office building located on a 13.62-acre site. The purchase price has been allocated as $ 4,640,000 , $ 1,600,000 , and $ 325,000 for the facility, land, and tenant improvements, respectively. Also included in the value of the property is $ 585,000 of intangible assets with an estimated useful life of approximating 3 years. The net book value of these assets as of December 31, 2025 approximated $ 6,231,00 . Of the total financed, approximately $ 226,000 of principal and accrued interest is classified as current portion of long-term debt, net, and the remaining balance of approximately $ 4,001,000 recorded as long-term debt, net of $ 4,000 in deferred financing costs. As of December 31, 2024 the outstanding principal and interest of approximately $ 4,424,000 , net of $ 27,000 in deferred financing costs, is classified as Current portion of long-term debt on assets held-for-sale, net on the consolidated balance sheet. Interest expense for the years ended December 31, 2025 and 2024 approximated $ 186,000 and $ 196,000 , respectively. On October 13, 2021, LVAM entered into loan agreement with BMIC International (“BMIC International Loan”), a related party, whereas LVAM borrowed the principal amount of $ 3,000,000 , with interest to be charged at a variable rate to be adjusted at the maturity date. The BMIC International Loan contains an auto renewal period of three months, with a maturity date of January 2026 as of December 31, 2025. As of December 31 2025, and December 31, 2024, the outstanding principal and interest of approximately $ 33,000 and $ 463,000 , respectively, are included in Current portion of long-term debt – related party, net on the consolidated balance sheet. On October 13, 2021, LVAM entered into a loan agreement with Lee Wilson Tsz Kin (“Wilson Loan”), a related party, whereas LVAM borrowed the principal amount of $ 3,000,000 , with interest to be charged at a variable rate to be calculated at the maturity date. The Wilson Loan contains an auto renewal period of three months, with a maturity date of January 2026 as of December 31, 2025. As of December 31, 2025, and December 31, 2024, the outstanding principal and interest of approximately $ 145,000 and $ 145,000 , respectively, are included in Current portion of long-term debt – related party, net on the consolidated balance sheet. On November 2, 2021, AMRE LifeCare entered into a loan agreement (“LifeCare Agreement”) with Pinnacle Bank, (“Pinnacle Bank”) in the amount of $ 40,300,000 . The LifeCare Agreement supported the acquisition of three medical facilities located in Fort Worth, Texas, Plano, Texas, and Pittsburgh, Pennsylvania for a purchase price of $ 62,000,000 . These assets are classified as investments, real estate on the consolidated balance sheet. The purchase price has been allocated as $ 32,100,000 , $ 12,100,000 , and $ 1,500,000 for the facility, land and site improvements, respectively. Also included in the value of the property is $ 15,901,000 of intangible assets with estimated useful lives ranging from 1 to 11 years. The LifeCare Agreement calls for the principal amount of the in equal, consecutive monthly installments based upon a twenty-five (25) year amortization of the original principal amount of the LifeCare Agreement at an initial rate of interest equal to the interest rate determined in accordance as of July 29, 2022 provided, however, such rate of interest shall not be less than 4.28 %, with the first such installment being payable on August 29, 2022 and subsequent installments being payable on the first day of each succeeding month thereafter until the maturity date, at which time any outstanding principal and interest is due in full. The affective interest rate at December 31, 2025 was 8.1 %. As of December 31, 2025, the outstanding principal and interest of the LifeCare agreement approximates $ 37,401,000 and is included Current portion of long-term debt, net on the accompanying balance sheet. As of December 31, 2024 the outstanding principal and interest balance approximated and is included in Current portion of long-term debt, net on the consolidated balance sheet. Interest expense for the years ended December 31, 2025 and 2024 approximated $ 2,952,000 and $ 3,861,000 , respectively. This note is in default and demand was made for final payment to be made by December 22, 2023. As of December 31, 2025, this amount is past due. 49 On March 17, 2022, AMRE Winter Haven, LLC (“AMRE Winter Haven”) and Pinnacle Bank (“Pinnacle”) entered into a term loan (“Pinnacle Loan”) whereas Pinnacle lent to AMRE Winter Haven the principal sum of $ 2,990,000 , maturing on March 7, 2024 to acquire a medical facility located in Winter Haven, Florida for a purchase price of $ 4,500,000 . The assets acquired are classified as investments, real estate on the consolidated balance sheet. The purchase price has been allocated as $ 3,200,000 , $ 1,000,000 , and $ 222,000 for the facility, land and site and tenant improvements, respectively. Also included in the value of the property is $ 29,000 of intangible assets with an estimated useful life of approximately 5 years. Payments are to be made in equal, consecutive installments based on a 25 -year amortization period with interest at 4.28 %. This note was assumed by SMS Financial on August 15, 2024, in the amount of $2,960,000 and refinanced with American Savings Life Insurance Company (“American Savings Note”) on August 29, 2025 in the amount of $ 3,250,000 . This note has an annual interest rate of 7.99 % and requires monthly installments of principal and interest of approximately $ 22,000 beginning on October 1, 2025 with a ballon payment at maturity on September 1, 2026. The outstanding principal and interest, approximates $ 3,040,000 and is included in Current portion of long-term debt, net on the accompanying consolidated balance sheet at December 31, 2024. Interest expense for the years ended December 31, 2025 and 2024 approximated $ 322,000 and $ 251,000 , respectively. This property located in Winter Haven FL was sold during December of 2025 and this note was repaid in full as of December 31st 2025. On March 30, 2023, Premier Packaging, a subsidiary of the Company entered into a loan and security agreement with Bank of America for the principal amount of $ 790,000 and shall accrued interest at the rate of 7.44 %. Principal and interest shall be repaid in the approximate amount of $ 14,000 through March 2029. This loan is collateralized by a Bobst Model Novacut and is guaranteed by DSS, Inc. As of December 31, 2025, the outstanding principal and interest approximates $ 482,000 of which $ 132,000 was included in the current portion of long-term debt, net, and the remaining balance of approximately $ 350,000 recorded as long-term debt. As of December 31, 2024, the outstanding principal and interest approximates $ 605,000 of which $ 123,000 was included in the current portion of long-term debt, net, and the remaining balance of approximately $ 607,000 recorded as long-term debt. Interest expense for the years ended December 31, 2025 and 2024 approximated $ 41,000 and $ 50,000 , respectively. In August of 2025, DSS issued a $ 500,000 convertible promissory note to Alset, Inc. (“holder”), the Company’s largest shareholder and a related party, bearing interest at Prime ( 6.75 % at December 31, 2025). The first 12 months’ interest is to be paid in shares of the Company; thereafter, interest is prepaid annually in cash or shares at the holder’s election. The note is convertible at the holder’s option at a fixed $ 0.86 per share, is payable on demand (or July 31, 2028 if not demanded) and may be redeemed by the Company on or after the first anniversary. The Company is required to reserve sufficient authorized shares and maintain the listing/quotation of its common stock. Under ASU 2020-06 and ASC 815-40, the debt host’s embedded conversion feature is indexed to the Company’s own stock and is equity-classified; accordingly, no embedded derivative is bifurcated and the instrument is accounted for as single-unit debt using the effective interest method. Interest is recognized in interest expense; when settled in shares, a credit to APIC is recorded at the fair value of shares on settlement, and any prepaid interest is recorded as a discount/prepaid and amortized to expense over the related period. The outstanding principal and interest, approximates $ 512,000 and is included in Convertible note payable, related party on the accompanying consolidated balance sheet at December 31, 2025. A summary of scheduled principal payments of long-term debt, not including revolving lines of credit, subsequent to December 31, 2025 are as follows: SCHEDULE OF NOTES PAYABLE AND LONG-TERM DEBT Year Notes payable Convertible note payable - related party Notes payable - related party Total 2026 $ 38,314,000 $ 503,000 $ 188,000 $ 39,005,000 2027 948,000 - - 948,000 2028 996,000 - - 996,000 2029 4194,000 - - 494,000 2030 268,000 - - 268,000 Thereafter 3,010,000 - - 3,010,000 Total $ 44,030,000 $ 503,000 $ 188,000 $ 44,721,000 13. LEASE LIABILITIES The Company has operating leases predominantly for operating facilities. As of December 31, 2025, the remaining lease terms on our operating leases range from less than one 1 to eleven years . Renewal options to extend our leases have not been exercised due to uncertainty. Termination options are not reasonably certain of exercise by the Company. There is no transfer of title or option to purchase the leased assets upon expiration. There are no residual value guarantees or material restrictive covenants. There are no significant finance leases as of December 31, 2025. 50 Future minimum lease payments as of December 31, 2025, are as follows: Maturity of Lease Liability: SCHEDULE OF FUTURE MINIMUM LEASE PAYMENTS Totals 2026 $ 839,000 2027 808,000 2028 824,000 2029 840,000 2030 857,000 thereafter 3,217,000 Total lease payments 7,385,000 Less imputed interest ( 1,082,000 ) Present value of remaining lease payments $ 6,303,000 Current $ 611,000 Non-current $ 5,692,000 Weighted average remaining lease term (years) 8.7 Weighted average discount rate 3.8 % Cash payments made YTD $ 861,000 Total cash paid during the years ended December 31, 2025 and 2024 approximated $ 861,000 and $ 956,000 , respectively. 14. STOCKHOLDERS’ EQUITY DSS, Inc. Equity transactions – On January 4, 2024 the Company effected a reverse stock split of 1 for 20 . As of December 31, 2024 and December 31, 2023, there were 140,264,240 and 139,017,000 shares of our Common Stock issued and outstanding, respectively, which was converted to 7,066,772 and 6,950,858 shares, respectively. On December 10, 2024, DSS entered into a securities purchase agreement with Alset Inc., a related party, pursuant to which the Company agreed to sell and issue in a private placement an aggregate of 820,597 shares of the Company’s common stock for approximately $ 803,000 . On December 10, 2024, DSS entered into a securities purchase agreement with Heng Fai Ambrose Chan, the Chaiman of the Board of Directors and a related party, pursuant to which the Company agreed to sell and issue in a private placement an aggregate of 205,149 shares of the Company’s common stock for approximately $ 197,000 . On February 6, 2025, as a bonus for compensation awarded to Heng Fai Holdings Limited (“HFHL”), a Hong Kong Company, which is beneficially owned by Mr. Heng Fai Ambrose Chan, Director of DSS, Inc. HFHL was awarded 1,000,000 shares of the Company’s common stock, approximating $ 870,000 . The issuance was approved by the board of directors on January 31, 2025. On March 21, 2025, DSS, the parent company of Impact Biomedical, Inc. completed the sale of 499,800 shares of Impact Biomedical common stock. These shares were acquired by DSS during Impact’s initial public offering on September 16, 2024. The sale of these shares, which were previously held by DSS as part of its ownership interest in Impact, was completed for a total value of $ 1,500,000 , which represents the consideration received from the transaction. With this sale, the shares are now publicly held and are no longer held by DSS. On April 4, 2025, DSS, the parent company of Impact Biomedical, Inc. completed the sale of 890,800 shares of Impact Biomedical common stock. The sale of these shares, which were previously held by DSS as part of its ownership interest in Impact, was completed for a total approximate value of $ 845,000 , which represents the consideration received from the transaction. With this sale, the shares are now publicly held and are no longer held by DSS. On May 22, 2025, DSS, the parent company of Impact Biomedical, Inc. completed the sale of 115,600 shares of Impact Biomedical common stock. The sale of these shares, which were previously held by DSS as part of its ownership interest in Impact, was completed for a total approximate value of $ 63,000 , which represents the consideration received from the transaction. With this sale, the shares are now publicly held and are no longer held by DSS. On May 23, 2025, DSS, the parent company of Impact Biomedical, completed the sale of 45,400 shares of Impact Biomedical common stock. The sale of these shares, which were previously held by DSS as part of its ownership interest in Impact, was completed for a total approximate value of $ 24,000 , which represents the consideration received from the transaction. With this sale, the shares are now publicly held and are no longer held by DSS. Equity Incentive Plan – On June 20, 2013, the Company’s shareholders adopted the 2013 Employee, Director and Consultant Equity Incentive Plan (the “2013 Plan”). The 2013 Plan provides for the issuance of up to a total of 50,000 shares of common stock authorized to be issued for grants of options, restricted stock and other forms of equity to employees, directors and consultants. Under the terms of the 2013 Plan, options granted thereunder may be designated as options which qualify for incentive stock option treatment (“ISOs”) under Section 422A of the Internal Revenue Code, or options which do not qualify (“NQSOs”). During the year ended December 31, 2024, 5,333 options were forfeited. As of December 31, 2024, no shares remained available under this plan. On December 9, 2019, the Company’s shareholders adopted the 2020 Employee, Director and Consultant Equity Incentive Plan (the “2020 Plan”). The 2020 Plan provides for the issuance of an initial 241,204 shares of common stock authorized to be issued for grants of options, restricted stock and other forms of equity to employees, directors and consultants. In addition, on the first day of each calendar year, for a period of not more than ten (10) years, commencing January 1, 2021, or the first business day of the calendar year if the first day of the calendar year falls on a Saturday or Sunday, the shares available under this plan will automatically increase in an amount equal to the lesser of (i) five percent (5%) of the total number of shares of Common Stock outstanding as of December 31 of the preceding fiscal year or (ii) such number of shares of Common Stock as determined by the Board of Directors. Under the terms of the 2020 Plan, options granted thereunder may be designated as options which qualify for incentive stock option treatment (“ISOs”) under Section 422A of the Internal Revenue Code, or options which do not qualify (“NQSOs”). As of December 31, 2025, there are 673,436 shares available under this plan. Stock-Based Compensation – The Company records stock-based payment expense related to options and warrants based on the grant date fair value in accordance with FASB ASC 718. Stock-based compensation includes expense charges for all stock-based awards to employees, directors and consultants. Such awards include option grants, warrant grants, and restricted stock awards. During the year ended December 31, 2025, and 2024 the Company’s stock compensation approximated $ 0 . The Company did not issue any warrants in 2025 or 2024, nor did it have any outstanding warrants as of December 31, 2025 and 2024. 51 Impact BioMedical, Inc. Equity Transactions – On September 16, 2024, Impact Biomedical Inc., entered into an underwriting agreement (the “Underwriting Agreement”) with Revere Securities, LLC., as representative (the “Representative”) of the underwriters named therein (the “Underwriters”), pursuant to which the Company agreed to sell to the Underwriters in a firm commitment initial public offering (the “Offering”) an aggregate of 1,500,000 of the Company’s shares of common stock, par value $ 0.001 per share at a public offering price of $ 3.00 per share. On September 17, 2024, the Company closed the Offering. The total net proceeds to the Company from the Offering, after deducting discounts, expenses allowance and expenses, was approximately $ 3,726,000 . A final prospectus relating to this Offering was filed with the Commission on September 16, 2024. The shares of Common Stock were approved to list on the NYSE American under the symbol “IBO” and began trading there on September 16, 2024. The Company also issued warrants to the Representative and its affiliates (the “Representative’s Warrants”) warrants to purchase the number of shares of Common Stock in the aggregate equal to 5% of the Common Stock to be issued and sold in this offering (including any Shares of Common Stock sold upon exercise of the over-allotment option, if applicable). The Representative’s Warrants are exercisable for a price per share equal to 125% of the public offering price. The warrants are exercisable at any time, in whole or in part, commencing nine (9) months from the date of commencement of sales of the offering and ending on the third anniversary thereof. These warrants were not exercised and expired in September 2025. On February 26, 2025, IBO issued 36,433 shares of the Company’s common stock as payment of legal fees incurred associated with IBO’s IPO, registration of shares associated with its equity incentive plan as well as other related services. The legal fees received were valued at approximately $ 29,000 . On June 23, 2025, IBO issued 100,000 shares of IBO’s common stock as payment of legal fees incurred associated with IBO’s merger and share exchange agreement with Dr. Ashleys Limited. The legal fees received were valued at approximately $ 161,000 . Equity Incentive Plan – During 2023, the Company’s shareholders adopted the 2023 Employee, Director and Consultant Equity Incentive Plan (the “2023 Plan”). The 2023 Plan provides for the issuance of an initial 18,762,000 shares of common stock authorized to be issued for grants of options, restricted stock and other forms of equity to employees, directors and consultants. In addition, on the first day of each calendar year, for a period of not more than ten (10) years, commencing January 1, 2025, or the first business day of the calendar year if the first day of the calendar year falls on a Saturday or Sunday, the shares available under this plan will automatically increase in an amount equal to the lesser of (i) two percent (2%) of the total number of shares of Common Stock outstanding as of December 31 of the preceding fiscal year or (ii) such number of shares of Common Stock as determined by the Board of Directors. Under the terms of the 2023 Plan, options granted thereunder may be designated as options which qualify for incentive stock option treatment (“ISOs”) under Section 422A of the Internal Revenue Code, or options which do not qualify (“NQSOs”). As of December 31, 2025, there are 18,037,079 shares available under this plan. Stock-Based Compensation – The Company records stock-based payment expense related to options and warrants based on the grant date fair value in accordance with FASB ASC 718. Stock-based compensation includes expense charges for all stock-based awards to employees, directors and consultants. Such awards include option grants, warrant grants, and restricted stock awards. On October 1, 2024, 880,000 option grants with a purchase price of $ 3.00 per share were awarded to certain officers, directors and consultants of the Company. These options have various vesting periods, and all expire on October 31, 2031. Potential proceeds of these grants is $ 2,640,000 and are fair valued using a Black-Scholes model at approximately $ 50,000 . The Company record stock based compensation expense of approximately $ 19,000 for the year ended December 31, 2025 and is included in Sales, general and administrative compensation (inclusive of stock based compensation) on the accompanying Statement of Operations. These options were forfeited and replaced by stock grants to the Officers and Directors of Impact Biomedical totaling 3,200,000 shares. These shares became vested in January of 2026. There were no stock-based payments made during the twelve months ended December 31, 2024. 15. INCOME TAXES The Company accounts for income taxes in accordance with Accounting Standards Codification (“ASC”) Topic 740, Income Taxes , using the asset and liability method. Deferred tax assets and liabilities are recognized for the expected future tax consequences attributable to temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases, and for operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply in the years in which those temporary differences are expected to reverse or such carryforwards are expected to be utilized. The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the financial reporting and tax basis of assets and liabilities. Deferred tax assets are reduced, if deemed necessary, by a valuation allowance for the amount of tax benefits which are not expected to be realized. The following is a summary of the components giving rise to the income tax provision (benefit) for the years ended December 31: The provision (benefit) for income taxes consists of the following: SCHEDULE OF INCOME TAX PROVISION 2025 2024 Currently payable: Federal $ - $ - State - 8,000 Foreign - - Total currently payable - 8,000 Deferred: Federal ( 4,672,000 ) 256,000 State 70,000 ( 290,000 ) Foreign ( 9,000 ) ( 4,000 ) Total deferred ( 4,611,000 ) ( 38,000 ) Less: increase/(decrease) in allowance 4,611,000 38,000 Net deferred - - Total income tax provision $ - $ 8,000 52 Individual components of deferred tax assets and liabilities are as follows: SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES 2025 2024 Deferred tax assets: Net operating loss carry forwards $ 25,672,000 $ 19,201,000 Net operating loss IRC 382 limited 9,634,000 9,634,000 Unrealized loss on securities 4,407,000 4,243,000 Equity issued for services 197,000 194,000 Goodwill and other intangibles 95,000 84,000 Investment in pass-through entity 11,000 11,000 Deferred revenue 176,000 176,000 Operating Lease Liability 1,419,000 1,557,000 Depreciation and amortization 1,000 1,000 Other 2,480,000 3,094,000 Gross deferred tax assets 44,092,000 38,195,000 Deferred tax liabilities: Goodwill and other intangibles 3,367,000 1,567,000 Depreciation and amortization ( 61,000 ) 309,000 Right to Use Asset 1,311,000 1,455,000 Gross deferred tax liabilities 4,617,000 3,331,000 Less: valuation allowance ( 39,475,000 ) ( 34,864,000 ) Net deferred tax assets (liabilities) $ - $ - At December 31, 2025 and 2024, the Company has approximately $ 154.0 million and $ 126.2 million in federal net operating loss carry forwards (“NOLs”), respectively, available to reduce future taxable income. Under the provisions of the Internal Revenue Code, the net operating losses are subject to review and possible adjustment by the Internal Revenue Service and state tax authorities. Certain tax attributes are subject to an annual limitation as a result of certain cumulative changes in ownership interest of significant shareholders which could constitute a change of ownership as defined under Internal Revenue Code Section 382. For the year ended December 31, 2021, the Company has completed a full analysis of historical ownership changes and determined that a portion of the net operating losses have a limitation on future deductibility. Approximately $ 43.8 million of net operating losses incurred prior to 2020 will be unable to offset future taxable income and have been reserved via a valuation allowance to reduce the deferred tax asset to the expected realizable amount, leaving $ 2.9 million available for use which expire at various dates through 2038 and the residual which never expire. Additionally, at December 31, 2025 and 2024, the Company had approximately $ 20.7 million and $ 20.7 of California and Illinois NOL carry-forwards, respectively, which expire through 2043 . The NOL carry forwards may be limited in certain circumstances, including ownership change and have been fully reserved via a valuation allowance. The valuation allowance for deferred tax assets decreased approximately $ 4.6 million for the year ended December 31, 2025 and increased approximately $ 2.2 for the year ended December 31, 2024, The valuation allowance for deferred tax liability increased approximately $ 1.3 million in the year ended December 31, 2025 and decreased approximately $ 2.3 million for the year ended December 31, 2024. The differences between the United States statutory federal income tax rate and the effective income tax rate in the accompanying consolidated statements of operations are as follows: SCHEDULE OF EFFECTIVE INCOME TAX RATE RECONCILIATION 2025 2024 2025 2024 Statutory United States federal rate $ ( 5,766,000 ) 21.00 % ( 11,276,000 ) 21.00 % State income taxes net of federal benefit 63,000 ( 0.23 ) ( 210,000 ) 0.39 Permanent differences 13,000 ( 0.05 ) 5,286,000 ( 9.84 ) Foreign Rate 1,000 ( 0.00 ) - 0.00 NOL DTA Write-off 36,000 ( 0.13 ) 41,000 ( 0.08 ) other 1,042,000 ( 3.80 ) 6,142,000 ( 11.44 ) Change in valuation reserves 4,611,000 ( 16.79 ) 25,000 ( 0.05 ) Effective tax rate $ - 0.00 % $ 8,000 ( 0.02 )% The Company recognizes interest accrued and penalties related to unrecognized tax benefits in tax expense. During the years ended December 31, 2025 and 2024 the Company recognized no interest and penalties. The Company has taken no uncertain tax positions as of December 31, 2025 and 2024. Accordingly, the Company has recorded no liability for unrecognized tax benefits as of such dates, and no interest or penalties related to uncertain tax positions were recognized for the years then ended. The Company files income tax returns in the U.S. federal jurisdiction and various states. The tax years 2022-2024 generally remain open to examination by major taxing jurisdictions to which the Company is subject. 53 16. DEFINED CONTRIBUTION PENSION PLAN The Company maintains a qualified employee savings plans (the “401(k) Plan”) that qualifies as a deferred salary arrangement under Section 401(k) of the Internal Revenue Code and which covers all eligible employees. Employees generally become eligible to participate in the 401(k) Plan two months following the employee’s hire date. Employees may contribute a percentage of their earnings, subject to the limitations of the Internal Revenue Code. Commencing on January 1, 2018, the Company matched 100 % of the first 1% of employee contributions, then 50 % of additional contributions up to an aggregate maximum match of 3.5 %. The total matching contributions for 2025 and 2024 were approximately $ 133,000 and $ 154,000 , respectively. 17. COMMITMENTS AND CONTINGENCIES License Agreement – On March 19, 2022, Impact BioMedical entered into a License Agreement (“Equivir License”) with a third-party (“Licensee”) where the Licensor is granted the right, amongst other things, to develop, commercialize, and sell the Company’s Equivir technology. In exchange, the Licensee shall pay the Company a royalty of 5.5 % of net sales. Under the terms of the Equivir Agreement, the Company shall reimburse the Licensee for 50 % of the development costs provided that the development costs shall not exceed $ 1,250,000 . As of December 31, 2025 and December 31, 2024, a liability of $ 0 has been recorded in relation to the Equivir License. Employment Agreements – As of December 31, 2025, DSS has no employment or severance agreements with members of its management team. Its subsidiary Impact BioMedical has an employment agreement with it CEO Frank Heuszel in which Mr. Heuszel’s agreement contains a mandatory bonus clause of $ 150,000 for the first year of the employment term, $ 100,000 for the second year of the employment term, and $ 100,000 for the third year of the employment term. As of December 31, 2024, approximately $ 38,000 is accrued for year one of Mr. Heuszel’s bonus. As of December 31, 2025, approximately $ 96,000 is accrued for year one of Mr. Heuszel’s bonus and $ 25,000 for the second year of Mr. Heuszel’s bonus Contingent Litigation Payments – The Company retains the services of professional service providers, including law firms that specialize in intellectual property licensing, enforcement and patent law. These service providers are often retained on an hourly, monthly, project, contingent or a blended fee basis. In contingency fee arrangements, a portion of the legal fee is based on predetermined milestones or the Company’s actual collection of funds. The Company accrues contingent fees when it is probable that the milestones will be achieved, and the fees can be reasonably estimated. As of December 31, 2025 and 2024 the Company had not accrued any contingent legal fees pursuant to these arrangements. Contingent Payments – The Company is party to certain agreements with funding partners who have rights to portions of intellectual property monetization proceeds that the Company receives. As of December 31, 2025 and 2024, there are no contingent payments due. 54 18. SUPPLEMENTAL CASH FLOW INFORMATION The following table summarizes supplemental cash flows for the years ended December 31, 2025 and 2024: SCHEDULE OF SUPPLEMENTAL CASH FLOW INFORMATION 2025 2024 Cash paid for interest $ 1,502,000 $ 720,000 Cash paid for income taxes $ - $ 8,000 Non-cash investing and financing activities: Shares awarded in lieu of cash award $ 870,000 $ - Shares issued in lieu of cash as payment for legal services $ 190,000 $ - Extinguishment of debt $ 595,000 $ - Stock based compensation $ 13,000 $ 19,000 19. SEGMENT INFORMATION The Company reports its segment information to reflect the manner in which the Company’s chief operating decision maker (“CODM”) reviews and assesses performance. The Company’s Interim Chief Executive Officer has responsibilities as the CODM and reviews and assess the performance of the Company as a whole. The primary financial measures used by the CODM to evaluate performance and allocate resources are net income (loss) and operating income (loss). The CODM uses net income (loss) and operating income (loss) to evaluate the performance of the Company’s ongoing operations and as part of the Company’s internal planning and forecasting processes. Information on Net income (loss) and Operating income (loss) is disclosed in the Consolidated Statements of Operations. Segment expenses and other segment items are provided to the CODM on the same basis as disclosed in the Consolidated Statements of Operations. The CODM does not evaluate performance or allocate resources based on segment assets, and therefore such information is not presented in the notes to the financial statements. During the fourth quarter of 2025, we realigned our internal reporting to better reflect how management reviews operating results and allocates resources. As a result of this CODM realignment, Direct Marketing is no longer a reportable segment and is now reported within Corporate and Other or the year ended December 31, 2025. This change did not impact consolidated revenue, consolidated net income (loss), total assets, or cash flows for any period presented; it only impacted the presentation of segment information. Segment information for prior periods presented has been recast to conform to the current-period segment presentation. Our four reporting segments are: Premier Packaging: (“Premier”) Premier Packaging Corporation provides custom packaging services and serves clients in the pharmaceutical, nutraceutical, consumer goods, beverage, specialty foods, confections, photo packaging and direct marketing industries, among others. The group also provides active and intelligent packaging and document security printing services for end-user customers. In addition, the division produces a wide array of printed materials, such as folding cartons and paperboard packaging, security paper, vital records, prescription paper, birth certificates, receipts, identification materials, entertainment tickets, secure coupons and parts tracking forms. The division also provides resources and production equipment for our ongoing research and development of security printing, brand protection, consumer engagement and related technologies. Commercial Lending: (“Commercial Lending”) through its operating company, American Pacific Financial, Inc. (“APF”) represents our financing business line. is organized for the purposes of being a financial network holding company, focused providing commercial loans and on acquiring equity positions in (i) undervalued commercial bank(s), bank holding companies and nonbanking licensed financial companies operating in the United States, South East Asia, Taiwan, Japan and South Korea, and (ii) companies engaged in—nonbanking activities closely related to banking, including loan syndication services, mortgage banking, trust and escrow services, banking technology, loan servicing, equipment leasing, problem asset management, SPAC (special purpose acquisition company) consulting, and advisory capital raising services. From this financial platform, the Company shall provide an integrated suite of financial services for businesses that shall include commercial business lines of credit, land development financing, inventory financing, third party loan servicing, and services that address the financial needs of the world Gig Economy. Biotechnology: (“Biotech”) targets unmet, urgent medical needs and expands the borders of medical and pharmaceutical science. Biotech drives mission-oriented research, development, and commercialization of solutions for medical advances in human wellness and healthcare. By leveraging technology and new science with strategic partnerships, Biotech provides advances in drug discovery for the prevention, inhibition, and treatment of neurological, oncology and immuno-related diseases. Other exciting technologies include a breakthrough alternative sugar aimed to combat diabetes and functional fragrance formulations aimed at the industrial and medical industry. Securities and Investment Management: (“Securities”) Securities was established to develop and/or acquire assets in the securities trading or management arena, and to pursue, among other product and service lines, real estate investment funds, broker dealers, and mutual funds management. T 55 Approximate information concerning the Company’s operations by reportable segment for the twelve months ended December 31, 2025 and 2024 is as follows. Segment information for prior periods presented has been recast to conform to the current-period segment presentation. The Company relies on intersegment cooperation and management does no t represent that these segments, if operated independently, would report the results contained herein: SCHEDULE OF OPERATIONS BY REPORTABLE SEGMENT Year Ended December 31, 2025 Product Packaging Commercial Lending Biotechnology Securities Corporate/ Other Total Revenue $ 18,150,000 $ 45,000 $ 38,000 $ 2,524,000 $ - $ 20,757,000 Cost of Revenue 16,619,000 20,000 424,000 5,844,000 19,000 22,926,000 Gross profit (loss) 1,531,000 25,000 ( 386,000 ) ( 3,320,000 ) ( 19,000 ) ( 2,169,000 ) Operating expense 3,360,000 287,000 4,041,000 2,302,000 2,275,000 12,265,000 Operating income (loss) ( 1,829,000 ) ( 262,000 ) ( 4,427,000 ) ( 5,622,000 ) ( 2,294,000 ) ( 14,434,000 ) Other income (expense) ( 143,000 ) ( 236,000 ) 3,862,000 ( 11,904,000 ) ( 4,633,000 ) ( 13,054,000 ) Net income (loss) from operations before taxes $ ( 1,972,000 ) $ ( 498,000 ) $ ( 565,000 ) $ ( 17,526,000 ) $ ( 6,727,000 ) $ ( 27,488,000 ) Year Ended December 31, 2024 Product Packaging Commercial Lending Direct Marketing Biotechnology Securities Corporate Total Revenue $ 16,107,000 $ 226,000 $ - $ - $ 2,764,000 $ - $ 19,097,000 Cost of revenue 15,230,000 712,000 5,000 42,000 7,550,000 - 23,539,000 Gross profit (loss) 877,000 ( 486,000 ) ( 5,000 ) ( 42,000 ) ( 4,786,000 ) - ( 4,442,000 ) Operating expense 3,029,000 402,000 254,000 28,929,000 2,759,000 2,781,000 38,154,000 Operating income (loss) ( 2,152,000 ) ( 888,000 ) ( 259,000 ) ( 28,971,000 ) ( 7,545,000 ) ( 2,781,000 ) ( 42,596,000 ) Other income (expense) ( 159,000 ) ( 1,186,000 ) 81,000 ( 3,784,000 ) ( 6,822,000 ) 768,000 ( 11,102,000 ) Net income (loss) from operations before taxes ( 2,311,000 ) ( 2,074,000 ) ( 178,000 ) ( 32,755,000 ) ( 14,367,000 ) ( 2,013,000 ) ( 53,698,000 ) 56 The following tables disaggregate our business segment revenues by major source: SCHEDULE OF DISAGGREGATION OF REVENUE Printed Products Revenue Information: Twelve months ended December 31, 2025 Packaging Printing and Fabrication $ 17,710,000 Commercial and Security Printing 376,000 Real Property Rental Income 64,000 Total Printed Products Revenue $ 18,150,000 Twelve months ended December 31, 2024 Packaging Printing and Fabrication $ 15,639,000 Commercial and Security Printing 409,000 Real Property Rental Income 59,000 Total Printed Products Revenue $ 16,107,000 Commercial Lending Revenue Information: Twelve months ended December 31, 2025 Commercial lending $ 45,000 Total Commercial Lending Revenue $ 45,000 Twelve months ended December 31, 2024 Commercial lending $ 226,000 Total Commercial Lending Revenue $ 226,000 Biotechnology Revenue Information: Twelve months ended December 31, 2025 Retail internet sales 38,000 Total Biotechnology Revenue $ 38,000 Twelve months ended December 31, 2024 Retail internet sales $ - Total Biotechnology Revenue $ - Securities Revenue Information: Twelve months ended December 31, 2025 Rental $ 1,246,000 Commission 1,278,000 Total Securities Revenue $ 2,524,000 Twelve months ended December 31, 2024 Rental $ 1,792,000 Commission 972,000 Total Securities Revenue $ 2,764,000 57 20. RELATED PARTY TRANSACTIONS The Company owns 127,179,291 shares or approximately 4 % of the outstanding shares of Alset International Limited (“Alset Intl”), a company incorporated in Singapore and publicly listed on the Singapore Exchange Limited. This investment is classified as a marketable security and is classified as long-term assets on the consolidated balance sheets as the Company has the intent and ability to hold the investments for a period of at least one year. The Chairman of the Company, Mr. Heng Fai Ambrose Chan, is the Executive Director and Chief Executive Officer of Alset Intl. Mr. Chan is also the majority shareholder of Alset Intl as well as the largest shareholder of the Company. The fair value of the marketable security as of December 31, 2025, and December 31, 2024, was approximately $ 2,277,000 and $ 2,518,000 respectively. During the year ended December 31, 2025 and December 31, 2024, the Company recorded unrealized loss on this investment of approximately $ 242,000 and unrealized loss of $ 750,000 , respectively. On October 13, 2021, LVAM entered into loan agreement with BMIC International (“BMIC International Loan”), a related party, whereas LVAM borrowed the principal amount of $ 3,000,000 , with interest to be charged at a variable rate to be adjusted at the maturity date. The BMIC International Loan contains an auto renewal period of three months, with a maturity date of January 2026 as of December 31, 2025. As of December 31 2025, and December 31, 2024, the outstanding principal and interest of approximately $ 33,000 and $ 463,000 , respectively, are included in Current portion of long-term debt – related party, net on the consolidated balance sheet. On October 13, 2021, LVAM entered into a loan agreement with Lee Wilson Tsz Kin (“Wilson Loan”), a related party, whereas LVAM borrowed the principal amount of $ 3,000,000 , with interest to be charged at a variable rate to be calculated at the maturity date. The Wilson Loan contains an auto renewal period of three months, with a maturity date of January 2026 as of December 31, 2025. As of December 31, 2025, and December 31, 2024, the outstanding principal and interest of approximately $ 145,000 and $ 145,000 , respectively, are included in Current portion of long-term debt – related party, net on the consolidated balance sheet. The Company owns 81,836,908 shares of True Partners Capital Holding Limited (“True Partners”), a publicly listed company on the Hong Kong Stock Exchange. On February 28, 2022, the Company entered into a Stock Purchase Agreement with Alset EHome International Inc. (“AEI”), pursuant to which AEI has agreed to sell a subsidiary holding 62,336,908 shares of stock of True Partner Capital Holding Limited exchange for 17,570,948 shares of common stock of the Company (the “DSS Shares”). The Company’s Executive Chairman and a significant stockholder, Heng Fai Ambrose Chan is the Chairman, Chief Executive Officer and largest shareholder of AEI. Further, on February 20, 2025, the Company acquired an additional 19,500,000 shares of True Partners. The fair value of the marketable security as of December 31, 2025 and December 31, 2024, was approximately $ 4,206,000 and $ 3,815,000 , respectively. During the year ended December 31, 2025 and December 31, 2024, the Company recorded unrealized loss on this investment of approximately $ 609,000 and unrealized loss of $ 590,000 , respectively. On July 26, 2022, APF and VEII entered into a promissory note (“Note 8”) in the principal sum of $ 1,000,000 with interest of 8 % with all unpaid principal and interest due on July 26, 2024 . This note was amended so that all unpaid principal and interest is due July 26, 2025. The outstanding principal and interest as of December 31, 2025 and December 31, 2024 approximates $ 917,000 . This note was fully reserved for as of December 31, 2025 and December 31, 2024. Heng Fai Ambrose Chan, the Chairman of DSS, Inc is also the on the board of directors of VEII. On August 29, 2022, DSS Financial Management Inc and BMIC LLC, a related party, entered into a promissory note (“Note 6”) in the principal sum of $ 100,000 with interest of 8 %, is due in three quarterly installments beginning on September 14, 2022. All unpaid principal and interest was due on August 29, 2025 . The outstanding principal and interest at December 31, 2025, and December 31, 2024 approximated $ 86,000 , and was fully reserved for as of December 31, 2025 and December 31, 2024. DSS owns 24.9 % of the outstanding common shares of BMIC LLC. On August 29, 2024, APF entered into a promissory note with WestPark. This note has a principal balance of $ 459,000 , which incurs interest at a rate of 10.0 % with principal and interest due at the maturity date of April 27, 2026 . On November 1, 2024, monthly payments of approximately $ 28,000 are due with any unpaid interest and principal due at maturity. As of December 31, 2025, the outstanding principal and interest approximates $ 237,000 , which is classified as Current notes receivable on the accompanying consolidated balance sheet. As of December 31, 2024, the outstanding principal and interest approximates $ 450,000 , of which $ 337,000 is classified as Current notes receivable and the remaining $ 113,000 is classified as Non-current notes receivable – related party on the accompanying consolidated balance sheet. On May 8, 2023, DSS Financial Management Inc and BMIC LLC entered into a promissory note (“Note 7”) in the principal sum of $ 102,000 with interest at the prime rate plus 2 % with a maturity date of May 7, 2026 . The outstanding principal and interest at December 31, 2025, and December 31, 2024 approximated $ 110,000 , and was fully reserved for as of December 31, 2025 and December 31, 2024. DSS owns 24.9 % of the outstanding common shares of BMIC LLC. On December 10, 2024, DSS entered into a securities purchase agreement with Alset Inc., a related party, pursuant to which the Company agreed to sell and issue in a private placement an aggregate of 820,597 shares of the Company’s common stock for approximately $ 803,000 . On December 10, 2024, DSS entered into a securities purchase agreement with Heng Fai Ambrose Chan, the Chaiman of the Board of Directors and a related party, pursuant to which the Company agreed to sell and issue in a private placement an aggregate of 205,149 shares of the Company’s common stock for approximately $ 197,000 . In August of 2025, DSS issued a $ 500,000 convertible promissory note to Alset, Inc. (“holder”), the Company’s largest shareholder and a related party, bearing interest at Prime ( 6.75 % at December 31, 2025). The first 12 months’ interest is to be paid in shares of the Company; thereafter, interest is prepaid annually in cash or shares at the holder’s election. The note is convertible at the holder’s option at a fixed $ 0.86 per share, is payable on demand (or July 31, 2028 if not demanded) and may be redeemed by the Company on or after the first anniversary. The Company is required to reserve sufficient authorized shares and maintain the listing/quotation of its common stock. Under ASU 2020-06 and ASC 815-40, the debt host’s embedded conversion feature is indexed to the Company’s own stock and is equity-classified; accordingly, no embedded derivative is bifurcated and the instrument is accounted for as single-unit debt using the effective interest method. Interest is recognized in interest expense; when settled in shares, a credit to APIC is recorded at the fair value of shares on settlement, and any prepaid interest is recorded as a discount/prepaid and amortized to expense over the related period. The outstanding principal and interest, approximates $ 512,000 and is included in Convertible note payable, related party on the accompanying consolidated balance sheet at December 31, 2025. On February 6, 2025, as a bonus for compensation awarded to Heng Fai Holdings Limited (“HFHL”), a Hong Kong Company, which is beneficially owned by Mr. Heng Fai Ambrose Chan, Director of DSS, Inc., HFHL was awarded 1,000,000 shares of the Company’s common stock, approximating $ 870,000 . The issuance was approved by the board of directors on January 31, 2025. On March 21, 2025, DSS, the parent company of Impact Biomedical, Inc. completed the sale of 499,800 shares of Impact Biomedical common stock. These shares were acquired by DSS during Impact’s initial public offering on September 16, 2024. The sale of these shares, which were previously held by DSS as part of its ownership interest in Impact, was completed for a total value of $ 1,500,000 , which represents the consideration received from the transaction. With this sale, the shares are now publicly held and are no longer held by DSS. On April 4, 2025, DSS, the parent company of Impact Biomedical, Inc. completed the sale of 890,800 shares of Impact Biomedical common stock. The sale of these shares, which were previously held by DSS as part of its ownership interest in Impact, was completed for a total approximate value of $ 845,000 , which represents the consideration received from the transaction. With this sale, the shares are now publicly held and are no longer held by DSS. On May 22, 2025, DSS, the parent company of Impact Biomedical, Inc. completed the sale of 115,600 shares of Impact Biomedical common stock. The sale of these shares, which were previously held by DSS as part of its ownership interest in Impact, was completed for a total approximate value of $ 63,000 , which represents the consideration received from the transaction. With this sale, the shares are now publicly held and are no longer held by DSS. On May 23, 2025, DSS, the parent company of Impact Biomedical, completed the sale of 45,400 shares of Impact Biomedical common stock. The sale of these shares, which were previously held by DSS as part of its ownership interest in Impact, was completed for a total approximate value of $ 24,000 , which represents the consideration received from the transaction. With this sale, the shares are now publicly held and are no longer held by DSS. 21. SUBSEQUENT EVENTS The Company has evaluated all subsequent events and transactions through March 31, 2026 the date that the condensed consolidated financial statements were available to be issued and noted no subsequent events requiring financial statement recognition or disclosure other than noted below: On February 4, 2026, DSS entered into an underwriting agreement (the “Underwriting Agreement”) with Aegis Capital Corp. (“Aegis”), which provided for the issuance and sale by the Company and the purchase by the underwriter, in a firm commitment underwritten public offering of 900,000 shares of the Company’s common stock. Subject to the terms and conditions contained in the Underwriting Agreement, the shares were sold at a public offering price of $ 1.00 per share, less certain underwriting discounts and commissions. The Offering closed on February 5, 2026 and the Company received approximately $ 700,000 , net of expenses. DSS, Inc. asserted U.S. Patent No. 6,879,040, directed to surface-mountable electronic devices used in LED products, against Nichia Corporation and Nichia America Corporation in the United States District Court for the Central District of California. In March 2026, the United States Court of Appeals for the Federal Circuit affirmed the district court’s dismissal of the action on the ground that the asserted patent claims are invalid as indefinite under 35 U.S.C. § 112, effectively concluding the litigation. As such, the Company at December 31, 2025, released an accrual of approximately $ 897,000 associated with potential fees for this case. On March 26, 2026, Alset International Limited (“AIL”), a majority-owned subsidiary of Alset Inc. (the “Company”) entered into a securities purchase agreement (the “SPA”) with DSS pursuant to which AIL will loan DSS $ 2,450,000 , in exchange for a convertible promissory note (the “Note”) and warrants to purchase 16,554,055 shares of DSS common stock (the “Warrants”). The Note, SPA, and Warrants are collectively referred to herein as the “Transaction Documents.” The Note will bear a simple interest rate of 3 % per annum. Under the terms of the Note, AIL may convert any outstanding principal and interest into shares of DSS common stock at $ 0.74 per share upon notice prior to maturity of the Note five ( 5 ) years from the date of thereof. The Warrants to be issued to AIL are to purchase up to 16,554,055 shares of DSS common stock at an exercise price of $ 0.93 per share. The Warrants expire on their fifth anniversary. 58 ITEM 9 - CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE Effective June 27, 2025, the Audit Committee of the Board of Directors of DSS approved the dismissal of Grassi & Co., CPAs, P.C. (“Grassi”) as the Company’s independent registered public accounting firm and the engagement of HTL International, LLC. (“HTL”) as the Company’s new independent registered public accounting firm. The reports of Grassi on the Company’s consolidated financial statements for the fiscal years ended December 31, 2024 and 2023 did not contain an adverse opinion or disclaimer of opinion and were not qualified or modified as to uncertainty, audit scope, or accounting principles. During the fiscal years ended December 31, 2024 and 2023, and through June 27, 2025, there were no disagreements with Grassi on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure, which disagreements, if not resolved to the satisfaction of Grassi, would have caused Grassi to make reference thereto in its reports on the Company’s consolidated financial statements. During the fiscal years ended December 31, 2024 and 2023, and through June 27, 2025, there were no “reportable events” as that term is defined in Item 304(a)(1)(v) of Regulation S-K. During the fiscal years ended December 31, 2024 and 2023, and through the date of engagement, neither the Company nor anyone on its behalf consulted with HTL regarding (i) the application of accounting principles to a specified transaction, either completed or proposed, or the type of audit opinion that might be rendered on the Company’s consolidated financial statements, and no written report or oral advice was provided to the Company by HTL that HTL concluded was an important factor considered by the Company in reaching a decision as to any accounting, auditing, or financial reporting issue, or (ii) any matter that was either the subject of a disagreement, as defined in Item 304(a)(1)(iv) of Regulation S-K, or a reportable event under Item 304(a)(1)(v) of Regulation S-K.